Ionizable cationic lipids for RNA delivery
Novel lipid compositions enhance the delivery of nucleic acids to target cells, addressing the challenges of incorporation and targeting in anhydrous solvents and improving therapeutic efficacy.
Patent Information
- Application Number
- JP2023035835
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-01-31
- Filing Date
- 2023-03-08
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2037-12-20
AI Technical Summary
Current nucleic acid therapeutics face challenges in being easily incorporated into anhydrous organic or anhydrous polar aprotic solvents and effectively delivered to target cells and tissues, limiting their therapeutic efficacy.
Development of novel lipid compositions that facilitate intracellular delivery of biologically active molecules, including nucleic acids, by forming lipid nanoparticles that protect and target these molecules to specific tissues.
Enhances the delivery of nucleic acids to target cells, improving therapeutic efficacy by protecting them from degradation and ensuring they reach their intended sites of action.
Smart Images

Figure 0007594038000193 
Figure 0007594038000194 
Figure 0007594038000195
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Patent Application No. 15 / 387,067, filed December 21, 2016. [Background technology]
[0002] Several different types of nucleic acids are currently being developed as therapeutic agents for the treatment of several diseases. As these molecules are developed, there is a need to produce them in a form that is stable, has a long shelf life, and can be easily incorporated into anhydrous organic or anhydrous polar aprotic solvents to allow encapsulation of the nucleic acids without side reactions that may occur in polar aqueous or non-polar solvents.
[0003] The present description relates to novel lipid compositions that facilitate intracellular delivery of biologically active and therapeutic molecules. The description also relates to pharmaceutical compositions that include such lipid compositions and are useful for delivering therapeutically effective amounts of biologically active molecules into cells of a patient.
[0004] The delivery of therapeutic compounds to a subject is important for their therapeutic effect, and may be hindered by the limited ability of the compounds to reach target cells and tissues.The improvement of such compounds to enter target cells of tissues by various delivery means is important.The present description relates to novel lipids in compositions and preparation methods that facilitate targeted intracellular delivery of biologically active molecules.
[0005] Examples of biologically active molecules for which effective targeting to patient tissues is often not achieved include many proteins, including polynucleotides such as immunoglobulin proteins, genomic DNA, cDNA, or mRNA antisense polynucleotides; and many low molecular weight compounds, whether synthetic or naturally occurring, such as peptide hormones and antibiotics.
[0006] One of the fundamental challenges currently facing medical practitioners is that several different types of nucleic acids are currently being developed as therapeutics for the treatment of several diseases. These nucleic acids include mRNA for gene expression, DNA in gene therapy, plasmids, small interfering nucleic acids (siNA), siRNA, and microRNA (miRNA) for use in RNA interference (RNAi), antisense molecules, ribozymes, antagomirs, and aptamers. As these nucleic acids are developed, there is a need to produce lipid formulations that are easy to make and can be easily delivered to target tissues. Summary of the Invention [Means for solving the problem]
[0007] One embodiment of what is described is a compound of formula I, [ka] During the ceremony, R1 is a branched alkyl group of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl of 2 to 20 carbons, or a branched alkyl of 10 to 31 carbons; L1 and L2 are the same or different and each is a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a straight or branched alkylene of 1 to 6 carbons; a compound of formula I, wherein R4 and R5 are the same or different and each is hydrogen or a straight or branched chain alkyl of 1 to 6 carbons; and pharma- ceutically acceptable salts thereof.
[0008] Another embodiment of what is described is a compound of formula I, [ka] During the ceremony, R1 is a branched acyclic alkyl or alkenyl of 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L1 is a linear alkane of 1 to 15 carbons; R2 is a linear alkyl or alkenyl of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons, or a branched acyclic alkyl or alkenyl of 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L2 is a linear alkane of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons; X is O or S; R3 is a linear alkane of 1, 2, 3, 4, 5, or 6 carbons; R4 and R5 are the same or different and are each a straight or branched chain acyclic alkyl of 1, 2, 3, 4, 5, or 6 carbons; or a pharma- ceutically acceptable salt or solvate thereof.
[0009] In one embodiment, R1 has 8, 9, 10, 11, 12, 13, 14, 16, or 17 carbons.
[0010] In another embodiment, R1 comprises two identical alkyl or alkenyl groups.
[0011] In another embodiment, R1 comprises an alkenyl group.
[0012] In another embodiment, R2 is alkenyl.
[0013] In another embodiment, R2 is branched acyclic alkyl.
[0014] In another embodiment, L2 has 4, 5, 6, or 7 carbons.
[0015] Preferably, the compound is selected from the group consisting of compounds of formula ATX-0082, ATX-0085, ATX-0083, ATX-0121, ATX-0091, ATX-0102, ATX-0098, ATX-0092, ATX-0084, ATX-0095, ATX-0125, ATX-0094, ATX-0109, ATX-0110, ATX-0118, ATX-0108, ATX-0107, ATX-0093, ATX-0097, and ATX-0096. [ka] [ka] [ka] [ka]
[0016] Another embodiment of what is described is a compound of formula I, [ka] During the ceremony, R1 is a branched acyclic alkyl or alkenyl of 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L1 is a linear alkane of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons; R2 is a linear alkyl or alkenyl of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons, or a branched acyclic alkyl of 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L2 is a linear alkane of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons; X is O or S; R3 is a linear alkane of 1, 2, 3, 4, 5, or 6 carbons; R4 and R5 are the same or different and each is a straight or branched acyclic alkyl of 1, 2, 3, 4, 5, or 6 carbons; A 1 mM solution of the compound has a pKa of 5.6-7.0 as measured by fluorescence of 6-(p-toluidino)-2-naphthalenesulfone; The compound has a c-LogD value of 10 to 14. or a pharma- ceutically acceptable salt or solvate thereof.
[0017] In one embodiment, R1 has 12, 13, 14, 16, or 17 carbons.
[0018] In another embodiment, R1 comprises two identical alkyl or alkenyl groups.
[0019] In another embodiment, R1 comprises an alkyl group.
[0020] In another embodiment, R2 is alkenyl.
[0021] In another embodiment, R2 is branched acyclic alkyl.
[0022] In another embodiment, L1 and L2 independently have 1, 2, or 3 carbons.
[0023] In another embodiment, L1 and L2 both have 3 carbons.
[0024] In another embodiment, R3 is propylene or butylene.
[0025] In another embodiment, the compound has a c-LogD value of at least 11 and its measured pKa is more basic than 6.
[0026] In another embodiment, the compound has the formula ATX-0111, ATX-0132, ATX-01 34, ATX-0100, ATX-0117, ATX-0114, ATX-0115, ATX-0101, ATX-0106, ATX-0116, ATX-0086, ATX-0058, ATX-0081, ATX-0123, ATX-0122, ATX-0057, ATX-0088, ATX-0087, ATX-0124, ATX-0126, ATX-0129, and ATX-0123. [ka] [ka] [ka] [ka] [ka] [ka]
[0027] Another embodiment of what is described is a compound of formula I, [ka] During the ceremony, R1 is a branched acyclic alkyl of 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L1 is a linear alkane of 1, 2, or 3 carbons; R2 is a linear alkenyl of 8, 9, 10, 11, or 12 carbons or a branched acyclic alkyl of 12, 13, 14, 16, or 17 carbons; L2 is a linear alkane of 1, 2, or 3 carbons; X is O or S; R3 is a 2 or 3 carbon straight chain alkane; R4 and R5 are the same or different and each is a 1 or 2 carbon straight or branched chain acyclic alkyl; or a pharma- ceutically acceptable salt or solvate thereof.
[0028] In another embodiment, the cationic lipids described herein are present in a pharmaceutical composition. The pharmaceutical composition preferably comprises lipid nanoparticles containing nucleic acid, preferably RNA polynucleotide. The lipid nanoparticles preferably increase the lifespan of the RNA in circulation. In another embodiment, upon administration of the pharmaceutical composition, the lipid nanoparticles therein deliver the nucleic acid to cells in the body. Preferably, the nucleic acid has activity to suppress the expression of a target gene. Alternatively, the nucleic acid is It has the activity of increasing the production of the protein it codes for when expressed in cells of the body.
[0029] Also described herein is a method for introducing a nucleic acid into a mammalian cell by using any of the above compositions. The cell may be in the liver, lung, kidney, brain, blood, spleen, or bone. The composition is preferably administered intravenously, subcutaneously, intraperitoneally, or intrathecally. Preferably, the compositions described herein are used in a method for treating cancer or an inflammatory disease. The disease may be selected from the group consisting of immune disorders, cancer, renal disease, fibrotic disease, genetic abnormalities, inflammation, and cardiovascular disease. [Brief description of the drawings]
[0030] [Figure 1] The synthetic pathway of ATX-0043 from hexanoate (SM1), 4-aminobutanoic acid (SM2), and 4-bromobutyric acid (SM3) is shown. Intermediates (Int) 1-8 and reactions are described in Example 2.
[0031] [Diagram 2]The synthetic pathway of ATX-0057 from octanoate (SM1), 4-aminobutanoic acid (SM2), and 4-bromobutyric acid (SM3) is shown. Int1-8 and reactions are described in Example 3.
[0032] [Diagram 3] FIG. 3 shows the synthetic route of ATX-0058 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-7 and reactions are described in Example 4.
[0033] [Figure 4] FIG. 3 shows the synthetic route of ATX-0081 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-8 and reactions are described in Example 5.
[0034] [Diagram 5] FIG. 3 shows the synthetic route of ATX-0082 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-7 and reactions are described in Example 6.
[0035] [Figure 6] FIG. 3 shows the synthetic route of ATX-0086 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-8 and reactions are described in Example 7.
[0036] [Figure 7] FIG. 3 shows the synthetic route of ATX-0087 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-8 and reactions are described in Example 8.
[0037] [Figure 8] FIG. 3 shows the synthetic route of ATX-0088 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-8 and reactions are described in Example 9.
[0038] [Figure 9] FIG. 3 shows the synthetic route of ATX-0083 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-8 and reactions are described in Example 10.
[0039] [Figure 10] FIG. 3 shows the synthetic route of ATX-0084 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-8 and reactions are described in Example 11.
[0040] [Figure 11] FIG. 2 shows the synthetic route of ATX-0061 from SM1 and SM2, which is the same as FIG. 1. Int1-5 and reactions are described in Example 12.
[0041] [Figure 12] FIG. 2 shows the synthetic route of ATX-0063 from SM1 and SM2, which is the same as FIG. 1. Int1-5 and reactions are described in Example 13.
[0042] [Figure 13] FIG. 2 shows the synthetic route of ATX-0064 from SM1 and SM2, which is the same as FIG. 1. Int1-5 and reactions are described in Example 14.
[0043] [Figure 14] The synthesis route of ATX-0081 is shown. Int1-6 and reactions are described in Example 15.
[0044] [Figure 15] FIG. 3 shows the synthetic route of ATX-0085 from SM1, SM2, and SM3, which is the same as FIG. 2. Int1-11 and reactions are described in Example 16.
[0045] [Figure 16] The synthesis route of ATX-0134 is shown. Int1-6 and reactions are described in Example 17.
[0046] [Figure 17]FIG. 1 shows EPO mRNA levels (ng / mL) following injection into mice of 0.03 mg / kg and 0.1 mg / kg of mRNA in nanoparticles containing ATX-002, ATX-0057, ATX-0081, ATX-0082, ATX-0083, ATX-0084, ATX-0085, ATX-0086, or ATX-0087 cationic lipids.
[0047] [Figure 18] 1 shows the anti-Factor VII knockdown activity of liposomes with ATX-0057 and ATX-0058 versus the activity of ATX-002 and the control (PBS alone).
[0048] [Figure 19] 1 shows the anti-EPO knockdown activity of liposomes bearing ATX-0057 versus the activity of ATX-002. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0049] definition "At least one" means one or more (eg, 1-3, 1-2, or 1).
[0050] "Composition" means a product comprising the specified ingredients in the specified amounts, as well as any product that results directly or indirectly from combining the specified ingredients in the specified amounts.
[0051] "In combination with" refers to the administration of a compound of formula I with another agent in a treatment method of the invention, which means that the compound of formula I and the other agent are administered sequentially or simultaneously in separate dosage forms, or simultaneously in the same dosage form.
[0052] "Mammal" means a human or other mammalian animal, or a human.
[0053] "Patient" means both humans and other mammals, preferably humans.
[0054] "Alkyl" is a saturated ofIt means a straight or branched hydrocarbon chain. In various embodiments, the alkyl group has 1 to 18 carbons, i.e., is a C1-C18 group, or is a C1-C 12 A is a C1-C6 group, or a C1-C4 group. Independently, in various embodiments, the alkyl group has zero branches (i.e., straight chain), one branch, two branches, or three or more branches. An "alkenyl" is an unsaturated alkyl that may have one double bond, two double bonds, or three or more double bonds. An "alkynyl" is an unsaturated alkyl that may have one triple bond, two triple bonds, or three or more triple bonds. The alkyl chain may be optionally substituted with one substituent (i.e., the alkyl group is monosubstituted), or one to two substituents, or one to three substituents, or one to four substituents, and the like. The substituents may be selected from the group consisting of hydroxy, amino, alkylamino, boronyl, carboxy, nitro, cyano, and the like. When an alkyl group incorporates one or more heteroatoms, the alkyl group is referred to herein as a heteroalkyl group. When the substituents on an alkyl group are hydrocarbons, the resulting group is simply referred to as a substituted alkyl. In various aspects, the alkyl group, including substituents, has less than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, or 7 carbons.
[0055] "Lower alkyl" means a group having 1 to 6 carbons in the chain which may be straight or branched. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and hexyl.
[0056] "Alkoxy" means an alkyl-O- group, where alkyl is as defined above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and heptoxy. The bond to the parent moiety is through the ether oxygen.
[0057] "Alkoxyalkyl" means an alkoxy-alkyl- group in which the alkoxy and alkyl are as previously described. Preferred alkoxyalkyls contain a lower alkyl group. The bond to the parent moiety is through the alkyl.
[0058] "Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls contain a lower alkyl group. The bond to the parent moiety is through the aryl.
[0059] "Aminoalkyl" means an NH2-alkyl- group attached to the parent moiety through an alkyl group, where alkyl is as defined above.
[0060] "Carboxyalkyl" means a HOOC-alkyl- group attached to the parent moiety through an alkyl group, in which alkyl is as defined above.
[0061] "Commercially available chemicals" and chemicals used in the examples described herein can be obtained from standard commercial sources, including, for example, Acros Organics (Pittsburgh, Pa.), Sigma-Adrich Chemical (Milwaukee, Wis.), Avocado Research (Lancashire, UK), Bionet (Cornwall, UK), Boron Molecular (Research Triangle Park, NC), Combi-Blocks (San Diego, Calif.), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, Pa.), Frontier Scientific (Logan, Utah), ICN Biomedicals, Inc. (Costa Mesa, Calif.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. (Cornwall, UK), Pierce Chemical Co. (Rockford, Ill.), Riedel de Haen (Hannover, Germany), Spectrum Quality Products, Inc. (New Brunswick, NJ), TCI America (Portland, Oreg.), and Wako Chemicals USA, Inc. (Richmond, Va.).
[0062] "Compounds described in the chemical literature" can be identified through reference books and databases covering chemical compounds and chemical reactions, as known to those of skill in the art. Suitable reference books and articles detailing the synthesis of reactants useful in the preparation of the compounds disclosed herein or providing references to literature describing the preparation of the compounds disclosed herein include, for example, "Synthetic Organic Chemistry," John Wiley and Sons, Inc., 1989, 1991, 1992, 1993, 1994, 1995, 1996, 1998, 1999, 1999, 1999, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1999, 1999, 1999, 1998, 1999, 1999, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1998, 1999, 1999, 1999, 1999, 1990 ...0, 1991, 1992, 1993, d Sons, Inc. New York, SRSandler et al, "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983, HOHouse, "Modern Synthetic Reactions," 2nd Ed., WA Benjamin, Inc. Menlo Park, Calif., 1972, TLGlichrist, "Heterocyclic Chemistry," 2nd Ed. John Wiley and Sons, New York, 1992, J. March, "Advanced Organic Chemistry: reactions, Mechanisms and Structure," 5th Ed., Wiley Interscience, New York, 2001; specific and similar reactants may also be identified through the index of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, available in most public and university libraries, and through online databases (American Chemical Society, Washington, DC, can be contacted for details). Chemicals that are known in catalogs but not commercially available can be prepared by custom chemical synthesis houses, and many of the standard chemical supply houses (such as those listed above) offer custom synthesis services.
[0063] "Halo" means a fluoro, chloro, bromo, or iodo group, with fluoro, chloro, or bromo being preferred, and fluoro and chloro being more preferred.
[0064] "Halogen" means fluorine, chlorine, bromine or iodine, with fluorine, chlorine and bromine being preferred.
[0065] "Heteroalkyl" means saturated or unsaturated, straight or branched, a chain containing carbon, and at least one heteroatom. A heteroalkyl group can have, in various embodiments, one heteroatom, or one to two heteroatoms, or one to three heteroatoms, or one to four heteroatoms. In one aspect, a heteroalkyl chain contains 1 to 18 (i.e., 1 to 18) member atoms (carbon and heteroatoms), and in various embodiments, 1 to 12, or 1 to 6, or 1 to 4 member atoms. Independently, in various embodiments, a heteroalkyl group has zero branches (i.e., straight chain), one branch, two branches, or three or more branches. Independently, in one embodiment, a heteroalkyl group is saturated. In another embodiment, a heteroalkyl group is unsaturated. In various embodiments, an unsaturated heteroalkyl group can have one double bond, two double bonds, three or more double bonds, and / or one triple bond, two triple bonds, or three or more triple bonds. A heteroalkyl chain can be substituted or unsubstituted. In one embodiment, the heteroalkyl chain is unsubstituted. In another embodiment, the heteroalkyl chain is substituted. A substituted heteroalkyl chain can have one substituent (i.e., by monosubstitution) or can have, for example, 1 to 2 substituents, or 1 to 3 substituents, or 1 to 4 substituents. Exemplary heteroalkyl substituents include ester (-C(O)-OR) and carbonyl (-C(O)-).
[0066] "Hydroxyalkyl" means a HO-alkyl group where alkyl is as defined above. Preferred hydroxyalkyl groups contain a lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
[0067] "Hydrate" means a solvate where the solvent molecule is H2O.
[0068] "Lipid" refers to organic compounds that contain esters of fatty acids and are characterized by being insoluble in water but soluble in many organic solvents. Lipids are generally divided into at least three classes: (1) "simple lipids," which include fats and oils as well as waxes; (2) "complex lipids," which include phospholipids, glycolipids, cationic lipids, non-cationic lipids, neutral lipids, and anionic lipids, all of which are described in more detail herein; and (3) "derived lipids," such as steroids.
[0069] "Lipid particle" refers to a lipid formulation that can be used to deliver a therapeutic nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, etc.). In a preferred embodiment, the lipid particle is a nucleic acid-lipid particle that is typically formed from a cationic lipid, a non-cationic lipid (e.g., phospholipid), a complex lipid that prevents particle aggregation (e.g., PEG lipid), and optionally cholesterol. Typically, the therapeutic nucleic acid (e.g., mRNA) is encapsulated in the lipid portion of the particle, which can protect it from enzymatic degradation.
[0070] The lipid particles typically have an average diameter of 30nm to 150nm, 40nm to 150nm, 50nm to 150nm, 60nm to 130nm, 70nm to 110nm, 70nm to 100nm, 80nm to 100nm, 90nm to 100nm, 70 to 90nm, 80nm to 90nm, 70nm to 80nm, or 30nm, 35nm, 40nm, 45nm, 50nm, 55nm, 60nm, 65nm, 70nm, 75nm, 80nm, 85nm, 90nm, 95nm, 100nm, 105nm, 110nm, 115nm, 120nm, 125nm, 130nm, 135nm, 140nm, 145nm, or 150nm, and are substantially non-toxic. In addition, nucleic acids, when present in lipid particles of the present invention, are resistant in aqueous solution to degradation by nucleases.
[0071] "Lipid-encapsulated" refers to a lipid particle that provides a therapeutic nucleic acid, such as an mRNA, completely encapsulated, partially encapsulated, or both. In a preferred embodiment, the nucleic acid (e.g., the mRNA) is completely encapsulated in the lipid particle.
[0072] "Lipid complex" refers to a complex lipid that inhibits lipid particle aggregation. Such lipid complexes include, but are not limited to, PEG-lipid complexes, such as PEG conjugated to dialkyloxypropyl (e.g., PEG-DAA complexes), PEG conjugated to diacylglycerol (e.g., PEG-DAG complexes), PEG conjugated to cholesterol, PEG conjugated to phosphatidylethanolamine, and PEG conjugated to ceramide, cationic PEG lipids, polyoxazoline (POZ)-lipid complexes, polyamide oligomers, and mixtures thereof. PEG or POZ can be directly conjugated to lipids or linked to lipids via linker moieties. For example, any linker moiety suitable for linking PEG or POZ to lipids can be used, including non-ester-containing linker moieties and ester-containing linker moieties. In certain preferred embodiments, non-ester-containing linker moieties such as amides or carbamates are used.
[0073] "Amphipathic lipid" refers to a material in which the hydrophobic portion of the lipid material orients into the hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase. The hydrophilic character comes from the presence of polar or charged groups, such as carbohydrate, phosphate, carboxylate, sulfato, amino, sulfhydryl, nitro, hydroxyl, and other similar groups. Hydrophobicity can be imparted by the inclusion of non-polar groups, including, but not limited to, long chain saturated and unsaturated aliphatic hydrocarbon groups, and such groups substituted by one or more aromatic, alicyclic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.
[0074] Representative examples of phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine.Other compounds that do not contain phosphorus, such as sphingolipids, glycosphingolipid family, diacylglycerol, and β-acyloxyacid, are also within the group designated as amphipathic lipid.In addition, the above amphipathic lipids can be mixed with other lipids, including triglycerides and sterols.
[0075] "Neutral lipid" refers to a lipid species that exists in either uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerol.
[0076] "Non-cationic lipid" means an amphipathic lipid or a neutral lipid or an anionic lipid, and is described in more detail below.
[0077] "Anionic lipid" refers to lipids that are negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoylphosphatidylethanolamine, N-succinylphosphatidylethanolamine, N-glutarylphosphatidylethanolamine, lysylphosphatidylglycerol, palmitoyloleylphosphatidylglycerol (POPG), and other anionic modifying groups conjugated to neutral lipids.
[0078] "Hydrophobic lipid" refers to a compound having a non-polar group, including but not limited to long chain saturated and unsaturated aliphatic hydrocarbon groups, and such groups optionally substituted with one or more aromatic, alicyclic, or heterocyclic group(s).Suitable examples include but are not limited to diacylglycerol, dialkylglycerol, N-N-dialkylamino, 1,2-diacyloxy-3-aminopropane, and 1,2-dialkyl-3-aminopropane.
[0079] "Cationic lipids" and "amino lipids" are used interchangeably and refer to those lipids and their salts that have one, two, three or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group). Cationic lipids are typically selected from those lipids that have a pH greater than or equal to the pK a It is protonated (i.e. positively charged) at a pH below pK a The cationic lipids of the present invention may also be referred to as titratable cationic lipids. In some embodiments, the cationic lipids are cationic lipids having a protonatable tertiary amine (e.g., pH-titratable) head group, C 1 -C 2 -C 3 -C 4 -C 5 -C 6 -C 7 -C 8 -C 9 -C 10 -C 11 -C 12 -C 13 -C 14 -C 15 -C 16 -C 17 -C 18 -C 19 -C 20 -C 21 -C 22 -C 23 -C 34 -C 25 -C 35 -C 40 -C 50 -C 65 -C 70 -C 85 -C 95 -C 100 -C 11 -C 12 -C 13 -C 14 -C 15 -C 16 -C 17 -C 18 -C 19 -C 22 -C 23 -C 15 -C 24 -C 16 -C 25 -C 17 -C 26 -C 18 -C 27 -C 38 -C 19 -C 28 -C 39 -C 29 -C 30 -C 31 -C 29 -C 32 -C 33 -C 14 -C 25 -C 34 -C 15 -C 26 -C 35 -C 16 -C 27 -C 36 -C 17 -C 28 -C 37 -C 18 -C 29 -C 38 -C 39 -C 40 -C 50 -C 61 -C 19 -C 25 -C 39 -C 19 -C 26 -C 39 -C 27 -C 39 -C 40 -C 50 - 18 Cationic lipids include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA, γ-DLenDMA, DLin--K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLen-C2K-DMA, y-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), DLin-M-C3-DMA (also known as MC3), and (DLin-MP-DMA) (also known as 1-Bl 1).
[0080] "Substituted" means substitution with a specified group other than hydrogen, or with one or more groups, moieties or radicals which may be the same or different, each eg, independently selected.
[0081] "Antisense nucleic acid" refers to a non-enzymatic nucleic acid molecule that binds to a target RNA through RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993 Nature 365,566) interactions and modifies the activity of the target RNA (for review, see Stein and Cheng, 1993 Science 261,1004 and Woolf et al., U.S. Pat. No. 5,849,902). Typically, an antisense molecule is complementary to a target sequence along a single continuous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule can bind to a substrate such that the substrate molecule forms a loop and / or an antisense molecule can bind to a substrate such that the antisense molecule forms a loop. Thus, an antisense molecule can be complementary to two (or even more) non-contiguous substrate sequences, or two (or even more) non-contiguous sequence portions of an antisense molecule can be complementary to a target sequence, or both. In addition, antisense DNA can be used to target RNA through DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. Antisense oligonucleotides can contain one or more RNAse H activating regions that can activate RNAse H cleavage of the target RNA. Antisense DNA can be chemically synthesized or expressed by using a single-stranded DNA expression vector or its equivalent. An "antisense RNA" is an RNA strand that has a sequence complementary to a target gene mRNA, which can induce RNAi by binding to the target gene mRNA. An "antisense RNA" is an RNA strand that has a sequence complementary to a target gene mRNA, which is believed to induce RNAi by binding to the target gene mRNA. A "sense RNA" has a sequence complementary to an antisense RNA, and anneals to its complementary antisense RNA to form an iNA. These antisense and sense RNAs are conventionally synthesized on an RNA synthesizer.
[0082] "Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single- or double-stranded form. The term encompasses nucleic acids containing synthetic, naturally occurring, and non-naturally occurring known nucleotide analogs or modified backbone residues or linkages that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to the reference nucleotide. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2'-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
[0083] "RNA" refers to a molecule that contains at least one ribonucleotide residue. "Ribonucleotide" refers to a nucleotide that has a hydroxyl group at the 2' position of a β-D-ribo-furanose moiety. The term includes double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, and modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution, and / or modification of one or more nucleotides. Such modifications can include the addition of non-nucleotide material, such as to the end(s) of an interfering RNA, or internally, for example, at one or more nucleotides of the RNA. The nucleotides in the RNA molecules of the invention can also include non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These modified RNAs can be referred to as analogs or analogs of naturally occurring RNA. As used herein, the terms "ribonucleic acid" and "RNA" refer to siRNA, antisense RNA, single-stranded RNA, It refers to molecules that contain at least one ribonucleotide residue, including microRNA, mRNA, non-coding RNA, and polyvalent RNA. A "ribonucleotide" is a nucleotide that has a hydroxyl group at the 2' position of a β-D-ribo-furanose moiety. These terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, and modified and altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution, modification, and / or alteration of one or more nucleotides. The alteration of RNA can include the addition of non-nucleotide material, such as to the end(s) of an interfering RNA, or internally, for example, to non-standard nucleotides, such as non-naturally occurring or chemically synthesized nucleotides or deoxyribonucleotides, at one or more nucleotides of the RNA nucleotides in the RNA molecule. These altered RNAs can be called analogs.
[0084] "Nucleotide" refers to natural (standard) and modified bases known in the art. Such bases are generally located at the 1' position of the nucleotide sugar moiety. Nucleotides generally comprise a base, a sugar, and a phosphate group. Nucleotides can be unmodified or modified in the sugar, phosphate, and / or base moieties (also referred to as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides, etc.; see, e.g., Usman and McSwiggen, supra; Eckstein et al., WO 92 / 07065; Usman et al., WO 93 / 15187; Uhlman & Peyman, supra, all incorporated herein by reference). There are several examples of modified nucleobases known in the art summarized by Limbach, et al., Nucleic Acids Res. 22:2183, 1994. Some non-limiting examples of base modifications that can be introduced into nucleic acid molecules include inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxybenzene, 3-methyluracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidine (e.g., 5-methylcytidine), 5-alkyluridine (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine), or 6-azapyrimidine or 6-alkylpyrimidine (e.g., 6-methyluridine), propyne, etc. (Burgin, et al., Biochemistry 35:14090,1996; Uhlman & Peyman, supra). In this embodiment, "modified base" refers to nucleotide bases other than adenine, guanine, cytosine, and uracil at 1' position or their equivalents.
[0085] "Complementary nucleotide bases" refers to paired nucleotide bases that form hydrogen bonds with each other. Adenine (A) pairs with thymine (T) or uracil (U) in RNA, and guanine (G) pairs with cytosine (C). Complementary segments or strands of nucleic acid that hybridize (i.e., join by hydrogen bonds) with each other. "Complementary" means that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence, either by traditional Watson-Crick or other non-traditional bonding modes.
[0086] "MicroRNA" (miRNA) means a single-stranded RNA molecule of 21-23 nucleotides in length that regulates gene expression; miRNAs are encoded by genes that are transcribed from DNA but not translated into proteins (non-coding RNA); instead, they are processed from a primary transcript known as pri-miRNA into short stem-loop structures called pre-miRNAs and finally into functional miRNAs. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression.
[0087] "Small interfering RNA (siRNA)" and "short interfering RNA" and "silencing RNA" are a class of double-stranded RNA molecules, 16-40 nucleotides in length, that play a variety of biological roles. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, which interferes with the expression of specific genes. In addition to their role in the RNAi pathway, siRNA also functions in RNAi-related pathways, such as antiviral mechanisms or in shaping the chromatin structure of genomes, and the complexities of these pathways are currently being elucidated.
[0088] "RNAi" refers to short intracellular RNAi sequences that are controlled by the RNA-induced silencing complex (RISC) and that interact with the catalytic RISC component argonaute. It refers to the RNA-dependent gene silencing process initiated by double-stranded RNA molecules. When double-stranded RNA or RNA-like iNA or siRNA is exogenous (arising from infection with a virus with an RNA genome or from transfected iNA or siRNA), the RNA or iNA is directly imported into the cytoplasm and cleaved into short fragments by the enzyme Dicer. The initiating dsRNA can also be endogenous (derived from the cell), such as pre-microRNA expressed from an RNA-coding gene in the genome. The primary transcript from such a gene is first processed to form the characteristic stem-loop structure of pre-miRNA in the nucleus, and then translocated to the cytoplasm where it is cleaved by Dicer. Thus, the two dsRNA pathways, exogenous and endogenous, converge in the RISC complex. The active components of the RNA-induced silencing complex (RISC) are endonucleases called Argonaute proteins, which cleave the target mRNA strand complementary to their bound siRNA or iNA. Since the fragments produced by Dicer are double-stranded, they can theoretically produce functional siRNA or iNA, respectively. However, only one of the two strands, known as the guide strand, binds to the Argonaute protein and directs gene silencing: the other anti-guide strand, or passenger strand, is degraded during RISC activation.
[0089] Compounds of Formula I
[0090] Reference to a compound of formula I herein is understood to include reference to its salts, unless otherwise indicated. As used herein, the term "salt(s)" refers to acid salts formed with inorganic and / or organic acids, as well as base salts formed with inorganic and / or organic bases. In addition, when a compound of formula I contains both a basic moiety, such as, but not limited to, pyridine or imidazole, and an acidic moiety, such as, but not limited to, carboxylic acid, a zwitterion ("internal salt") may be formed, and is included within the term "salt(s)" as used herein. The salt may be a pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salt, although other salts are also useful. A salt of a compound of formula I may be formed, for example, by reacting a compound of formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium, followed by lyophilization.
[0091] Exemplary acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxybutanoate, and the like. Salts of phenylpropionate, tert-butyl ether, ... 19, P. Gould, International J. Pharmaceutics (1986) 33 201-217, Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York, and in The Orange Book (Food & Drug Administration, Washington, DC, on their website), the disclosures of which are incorporated herein by reference.
[0092] Exemplary basic salts include alkali metal salts such as ammonium, sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (e.g., organic amines), such as benzathine, dicyclohexylamine, hydrabamine (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glucamide, t-butylamine, and salts with amino acids such as arginine or lysine. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfate), long chain halides (e.g., decyl chlorides, bromides, and iodides, lauryl, myristyl, and stearyl), aryl alkyl halides (e.g., benzyl and phenethyl bromides), and the like.
[0093] All such acid and base salts are intended to be pharma- ceutically acceptable salts within the scope of this disclosure, and all acid and base salts are considered equivalent, for purposes of this disclosure, to the free form of the corresponding compounds of Formula I.
[0094] Compounds of formula I can exist in unsolvated and solvated forms, including hydrated forms. In general, solvated forms with pharma- ceutically acceptable solvents such as water, ethanol, and the like, are equivalent to unsolvated forms for purposes of this disclosure.
[0095] The compounds of Formula I, and their salts, solvates, may exist in their tautomeric form (for example, as an amide or imino ether), and all such tautomeric forms are contemplated herein as part of the present disclosure.
[0096] Also within the scope of this disclosure are polymorphs of the compounds of this disclosure (ie, polymorphs of the compounds of formula I are within the scope of this disclosure).
[0097] All stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the compounds (including salts, solvates, and prodrugs of the compounds, and salts and solvates of the prodrugs), including enantiomeric forms (which may exist even in the absence of an asymmetric carbon), rotamer forms, atropisomers, and diastereomeric forms, which may exist due to asymmetric carbons on various substituents, are contemplated within the scope of the present disclosure. Individual stereoisomers of the compounds of the present disclosure may, for example, be substantially free of other isomers or may be mixed, for example, as racemates or with all other or selected stereoisomers. The chiral centers of the compounds of the present disclosure are S, C, D, E, E, F, E, G, H, I ... or R configuration. Use of the terms "salts," "solvates," and the like are intended to apply equally to salts and solvates of the enantiomers, stereoisomers, rotamers, tautomers, racemates, or prodrugs of the disclosed compounds.
[0098] Classes of compounds that can be used as chemotherapeutic agents (antitumor agents) include alkylating agents, antimetabolites, natural products and their derivatives, hormones and steroids (including synthetic analogues), and synthetic drugs. Examples of compounds within these classes are provided below. . lipid particles
[0099] The compound of formula I is included in a lipid composition comprising a bilayer of nanoparticles or lipid molecules, and a pharma- ceutically acceptable salt thereof. The lipid bilayer preferably further comprises a neutral lipid or polymer. The lipid composition preferably comprises a liquid medium. The composition preferably further encapsulates a nucleic acid. The nucleic acid preferably has an activity of suppressing the expression of a target gene by utilizing RNA interference (RNAi). The lipid composition preferably further comprises a nucleic acid and a neutral lipid or polymer. The lipid composition preferably encapsulates a nucleic acid.
[0100] The description provides lipid particles that include one or more therapeutic mRNA molecules encapsulated within the lipid particle.
[0101] In some embodiments, the mRNA is fully encapsulated within the lipid portion of the lipid particle such that the mRNA in the lipid particle is resistant in aqueous solution to nuclease degradation. In other embodiments, the lipid particles described herein are substantially non-toxic to mammals, such as humans. The lipid particles typically have an average diameter of 30 nm to 150 nm, 40 nm to 150 nm, 50 nm to 150 nm, 60 nm to 130 nm, 70 nm to 110 nm, or 70 to 90 nm. The lipid particles of the present invention also typically have a lipid:RNA ratio (mass / mass ratio) of 1:1 to 100:1, 1:1 to 50:1, 2:1 to 25:1, 3:1 to 20:1, 5:1 to 15:1, or 5:1 to 10:1, or 10:1 to 14:1, or 9:1 to 20:1. In one embodiment, the lipid particles have a lipid:RNA ratio (mass / mass ratio) of 12:1. In another embodiment, the lipid particles have a lipid:mRNA ratio (mass / mass) of 13:1.
[0102] In a preferred embodiment, the lipid particles comprise an mRNA, a cationic lipid (e.g., one or more cationic lipids or salts thereof described herein), a phospholipid, and a conjugated lipid (e.g., one or more PEG-lipid conjugates) that inhibit particle aggregation. The lipid particles may also comprise cholesterol. The lipid particles may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more mRNAs expressing one or more polypeptides.
[0103] In nucleic acid-lipid particles, mRNA can be completely encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation. In a preferred embodiment, the lipid particle containing mRNA is completely encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation. In certain cases, the mRNA in the lipid particle is not substantially degraded after exposing the particle to nuclease at 37°C for at least 20, 30, 45, or 60 minutes. In certain other cases, the mRNA in the lipid particle is not substantially degraded after incubating the particle in serum at 37°C for at least 30, 45, or 60 minutes, or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours. In other embodiments, the mRNA is complexed with the lipid portion of the particle. One advantage of the present formulations is that the nucleic acid-lipid particle compositions are substantially non-toxic to mammals, such as humans.
[0104] "Completely encapsulated" means that the nucleic acid (e.g., mRNA) in the nucleic acid-lipid particle is not significantly degraded after exposure to serum or nuclease assays that would significantly degrade free RNA.When fully encapsulated, preferably less than 25% of the nucleic acid in the particle is degraded in a process that would normally degrade 100% of free nucleic acid, more preferably less than 10%, and most preferably less than 5% of the nucleic acid in the particle is degraded."Completely encapsulated" also means that the nucleic acid-lipid particle does not rapidly degrade into its component parts upon in vivo administration.
[0105] In the context of nucleic acids, complete encapsulation can be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid. Encapsulation is determined by adding the dye to the liposome formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of non-ionic detergent. Detergent-mediated disruption of the liposome bilayer releases the encapsulated nucleic acid, allowing it to interact with the membrane-impermeable dye. Nucleic acid encapsulation can be calculated as E=(I0-I) / I0, where / and I0 refer to the fluorescence intensity before and after the addition of detergent.
[0106] In other embodiments, the present invention provides nucleic acid-lipid particle compositions comprising a plurality of nucleic acid-lipid particles.
[0107] The lipid particles contain mRNA that is fully encapsulated within the lipid portion of the particle, resulting in 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80%-100%, 90%-100%, 30%-95%, 40%-95%, 50%-95%, 60%-95%, 70%-95%, 80%-95%, 85%-95%, 90%-95%, 30%-90%, 40%- 90%, 50%-90%, 60%-90%, 70%-90%, 80%-90%, or at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any percentage or range thereof) of the particles have mRNA encapsulated therein.
[0108] Depending on the intended use of the lipid particles, the ratio of the components can be varied, and the delivery efficiency of a particular formulation can be measured using assays known in the art. Cationic lipids
[0109] The description includes the synthesis of certain cationic lipid compounds. These compounds are particularly suitable for delivering polynucleotides to cells and tissues, as shown in the following sections. The lipomacrocycle compounds described herein can be used for other purposes, as well as for example, recipients and additives.
[0110] The cationic lipid compounds can be synthesized using techniques known in the art. Those skilled in the art will recognize other methods for producing these compounds, as well as other compounds described.
[0111] Cationic lipid compounds may be combined with drugs to form microparticles, nanoparticles, liposomes, or micelles. Drugs delivered by particles, liposomes, or micelles may be in gas, liquid, or solid form, and drugs may be polynucleotides, proteins, peptides, or small molecules. Lipo-macrocycle compounds may be combined with other cationic lipid compounds, polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, or lipids to form particles. These particles may then be combined with pharmaceutical excipients as needed to form pharmaceutical compositions.
[0112] This description provides novel cationic lipid compounds and drug delivery systems based on the use of such cationic lipid compounds. The systems can be used in pharmaceutical / drug delivery technology to deliver polynucleotides, proteins, small molecules, peptides, antigens, or drugs to patients, tissues, organs, or cells. These novel compounds can also be used as coatings, additives, excipients, materials, or materials for biotechnology.
[0113] The cationic lipid compounds described herein offer several different applications in drug delivery technologies. The amine-containing moieties of cationic lipid compounds can be used to complex polynucleotides, thereby enhancing their delivery and preventing their degradation. The cationic lipid compounds can also be used in the formation of picoparticles, nanoparticles, microparticles, liposomes, and micelles that contain the agent to be delivered. Preferably, the cationic lipid compounds are biocompatible and biodegradable, and the particles formed are also biodegradable and biocompatible and can be used to provide controlled, sustained release of the agent to be delivered. These and their corresponding particles can also respond to pH changes, considering that they are protonated at lower pH. They can also function as proton sponges in the delivery of agents to cells, causing endosome lysis.
[0114] In certain embodiments, the cationic lipid compounds are relatively non-toxic. The cationic lipid compounds may be biocompatible and biodegradable. The cationic lipids have a measured pK ranging from about 5.5 to about 7.5, more preferably from about 6.0 to about 7.0. a (in a formulation environment) may have a desired pK of about 3.0 to about 9.0 or about 5.0 to about 8.0. a The cationic lipid compounds described herein are particularly attractive for drug delivery for several reasons: they contain amino groups to interact with DNA, RNA, other polynucleotides, and other negatively charged drugs, to buffer pH, to protect the drug being delivered against endo-osmolysis, they can be synthesized from commercially available starting materials, and / or they are pH responsive and can be designed to have a desired pK a It can be operated with. Neutral Helper Lipids
[0115] Non-limiting examples of non-cationic lipids include lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetyl phosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (DPPG ... Examples of phospholipids include phospholipids such as palmitoyloleoyl-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, dielaidoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids can also be used. The acyl groups in these lipids are preferably C 10 ~C 24 It is an acyl group derived from a fatty acid having a carbon chain, for example, lauroyl, myristoyl, palmitoyl, stearoyl, or oleyl.
[0116] Further examples of non-cationic lipids include sterols such as cholesterol and its derivatives. Non-limiting examples of cholesterol derivatives include polar analogs such as 5α-cholestanol, 5α-coprostanol, cholesteryl-(2'-hydroxy)-ethyl ether, cholesteryl-(4'-hydroxy)-butyl ether, and 6-ketocholestanol; 5α-cholestane, cholestenone, 5α-cholestanone, 5α-cholestane ... non-polar analogs such as cholesteryl decanoate; and mixtures thereof. In a preferred embodiment, the cholesterol derivative is a polar analog such as cholesteryl-(4'-hydroxy)-butyl ether.
[0117] In some embodiments, the non-cationic lipid present in the lipid particle comprises or consists of a mixture of one or more phospholipids and cholesterol or its derivatives.In other embodiments, the non-cationic lipid present in the lipid particle comprises or consists of one or more phospholipids, for example, cholesterol-free lipid particle formulations.In yet other embodiments, the non-cationic lipid present in the lipid particle comprises or consists of cholesterol or its derivatives, for example, phospholipid-free lipid particle formulations.
[0118] Other examples of non-cationic lipids include phosphorus-free containing lipids such as, for example, stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerol ricinoleate, hexadecyl stearate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethylammonium bromide, ceramides, and sphingomyelin.
[0119] In some embodiments, the non-cationic lipid comprises 10 mol% to 60 mol%, 20 mol% to 55 mol%, 20 mol% to 45 mol%, 20 mol% to 40 mol%, 25 mol% to 50 mol%, 25 mol% to 45 mol%, 30 mol% to 50 mol%, 30 mol% to 45 mol%, 30 mol% to 40 mol%, 35 mol% to 45 mol%, 37 mol% to 42 mol%, or 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, or 45 mol% (or any percentage or range thereof) of the total lipid present in the particle.
[0120] In embodiments in which the lipid particle contains a mixture of phospholipids and cholesterol or a cholesterol derivative, the mixture may comprise up to 40 mol%, 45 mol%, 50 mol%, 55 mol%, or 60 mol% of the total lipid present in the particle.
[0121] In some embodiments, the phospholipid component in the mixture may comprise 2 mol%-20 mol%, 2 mol%-15 mol%, 2 mol%-12 mol%, 4 mol%-15 mol%, or 4 mol%-10 mol% (or any percentage or range thereof) of the total lipid present in the particle. In certain preferred embodiments, the phospholipid component in the mixture comprises 5 mol%-10 mol%, 5 mol%-9 mol%, 5 mol%-8 mol%, 6 mol%-9 mol%, 6 mol%-8 mol%, or 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any percentage or range thereof) of the total lipid present in the particle.
[0122] In other embodiments, the cholesterol component in the mixture may comprise 25 mol%-45 mol%, 25 mol%-40 mol%, 30 mol%-45 mol%, 30 mol%-40 mol%, 27 mol%-37 mol%, 25 mol%-30 mol%, or 35 mol%-40 mol% (or any percentage or range thereof) of the total lipid present in the particle. In certain preferred embodiments, the cholesterol component in the mixture comprises 25 mol%-35 mol%, 27 mol%-35 mol%, 29 mol%-35 mol%, 30 mol%-35 mol%, 30 mol%-34 mol%, 31 mol%-33 mol%, or 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, or 35 mol% (or any percentage or range thereof) of the total lipid present in the particle.
[0123] In embodiments in which the lipid particle does not contain phospholipids, cholesterol or a derivative thereof may comprise up to 25 mol%, 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, 55 mol%, or 60 mol% of the total lipid present in the particle.
[0124] In some embodiments, cholesterol or a derivative thereof in a phospholipid-free lipid particle formulation may comprise 25 mol% to 45 mol%, 25 mol% to 40 mol%, 30 mol% to 45 mol%, 30 mol% to 40 mol%, 31 mol% to 39 mol%, 32 mol% to 38 mol%, 33 mol% to 37 mol%, 35 mol% to 45 mol%, 30 mol% to 35 mol%, 35 mol% to 40 mol%, or 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, or 40 mol% (or any percentage or range thereof) of the total lipid present in the particle.
[0125] In other embodiments, the non-cationic lipid comprises 5 mol%-90 mol%, 10 mol%-85 mol%, 20 mol%-80 mol%, 10 mol% (e.g., phospholipids only), or 60 mol% (e.g., phospholipids and cholesterol or derivatives thereof) (or any percentage or range thereof) of the total lipid present in the particle.
[0126] The percentage of non-cationic lipid present in the lipid particle is a target amount, and the actual amount of non-cationic lipid present in the formulation can vary, for example, by ±5 mol %.
[0127] A composition containing a cationic lipid compound may be 30-70% cationic lipid compound, 0-60% cholesterol, 0-30% phospholipid, and 1-10% polyethylene glycol (PEG). Preferably, the composition is 30-40% cationic lipid compound, 40-50% cholesterol, and 10-20% PEG. In another preferred embodiment, the composition is 50-75% cationic lipid compound, 20-40% cholesterol, and 5-10% phospholipid, and 1-10% PEG. The composition may contain 60-70% cationic lipid compound, 25-35% cholesterol, and 5-10% PEG. The composition may contain up to 90% cationic lipid compound and 2-15% helper lipid.
[0128] The formulation may be, for example, a lipid particle formulation containing 8-30% compound, 5-30% helper lipid, and 0-20% cholesterol; 4-25% cationic lipid, 4-25% helper lipid, 2-25% cholesterol, 10-35% cholesterol-PEG, and 5% cholesterol-amine; or 2-30% cationic lipid, 2-30% helper lipid, 1-15% cholesterol, 2-35% cholesterol-PEG, and 1-20% cholesterol-amine; or up to 90% cationic lipid and 2-10% helper lipid, or even 100% cationic lipid. lipid complex
[0129] In addition to cationic, lipid particles described herein may further comprise lipid complexes. Complex lipids are useful in preventing particle aggregation. Suitable complex lipids include, but are not limited to, PEG-lipid complexes, cationic polymer-lipid complexes, and mixtures thereof.
[0130] In a preferred embodiment, the lipid conjugate is a PEG-lipid. Examples of PEG-lipids include PEG conjugated to dialkyloxypropyl (PEG-DAA), PEG conjugated to diacylglycerol (PEG-DAG), PEG conjugated to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramide, cholesterol, and the like. Examples of suitable PEG-conjugated polymers include, but are not limited to, PEG conjugated to PEG or its derivatives, and mixtures thereof.
[0131] PEG is a linear water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified according to their molecular weight and include: monomethoxypolyethyleneglycol (MePEG-OH), monomethoxypolyethyleneglycol-succinate (MePEG-S), monomethoxypolyethyleneglycol-succinimidyl succinate (MePEG-S-NHS), monomethoxypolyethyleneglycol-amine (MePEG-NH2), monomethoxypolyethyleneglycol-tresylate (MePEG-TRES), monomethoxypolyethyleneglycol-imidazolyl-carbonyl (MePEG-IM), as well as compounds containing terminal hydroxyl groups instead of terminal methoxy groups (e.g., HO-PEG-S, HO-PEG-S-NHS, HO-PEG-NH2).
[0132] The PEG moiety of the PEG-lipid conjugates described herein may comprise an average molecular weight ranging from 550 daltons to 10,000 daltons. In certain cases, the PEG moiety has an average molecular weight of 750 daltons to 5,000 daltons (e.g., 1,000 daltons to 5,000 daltons, 1,500 daltons to 3,000 daltons, 750 daltons to 3,000 daltons, 750 daltons to 2,000 daltons). In preferred embodiments, the PEG moiety has an average molecular weight of 2,000 daltons or 750 daltons.
[0133] In certain cases, PEG can be optionally substituted by alkyl, alkoxy, acyl or aryl groups.PEG can be directly conjugated to lipid or can be linked to lipid via a linker moiety.Any suitable linker moiety can be used to link PEG to lipid, including, for example, non-ester-containing linker moiety and ester-containing linker moiety.In a preferred embodiment, the linker moiety is a non-ester-containing linker moiety. Suitable non-ester containing linker moieties include, but are not limited to, amide (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (-NHC(O)O-), urea (-NHC(O)NH-), disulfide (-SS-), ether (-0-), succinyl (-(0)CCH2CH2C(0)-), succinamidyl (-NHC(0)CH2CH2C(0)NH-), ether, disulfide, and combinations thereof, such as linkers containing both carbamate and amide linker moieties. In a preferred embodiment, a carbamate linker is used to attach the PEG to the lipid.
[0134] In other embodiments, an ester-containing linker moiety is used to attach the PEG to the lipid. Suitable ester-containing linker moieties include, for example, carbonate (-OC(O)O-), succinoyl, phosphate ester (-O-(O)POH-O-), sulfonate ester, and combinations thereof.
[0135] Phosphatidylethanolamines having various acyl chain groups of various chain lengths and degrees of saturation can be conjugated to PEG to form lipid conjugates. Such phosphatidylethanolamines are commercially available or can be isolated or synthesized using conventional techniques known to those of skill in the art. 10 ~C 20 Phosphatidylethanolamines containing saturated or unsaturated fatty acids having carbon chain lengths in the range of 0.1 to 100 are preferred. Phosphatidylethanolamines having mono- or di-unsaturated fatty acids, as well as mixtures of saturated and unsaturated fatty acids, may also be used. Suitable phosphatidylethanolamines include dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoyl-phosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE). The present invention is not limited to these.
[0136] The term "diacylglycerol" or "DAG" refers to a diacylglycerol that is a glycerol having two fatty acyl chains R 1 and R 2 Both of which have 2-30 carbons attached independently to the 1- and 2-positions of glycerol by ester linkages. The acyl groups can be saturated or have different degrees of unsaturation. Suitable acyl groups include lauroyl (C 12 ), myristoyl (C 14 ), palmitoyl (C 16 ), stearoyl (C 18 ), and Icosoil (C 20 In a preferred embodiment, R 1 and R 2 are identical, i.e., R 1 and R 2 are both myristoyl (i.e. dimyristoyl), and R 1 and R 2 are both stearoyl (i.e. distearoyl).
[0137] The term "dialkyloxypropyl" or "DAA" includes compounds having two alkyl chains, R1 and R2, both of which, independently, have between 2 and 30 carbons. The alkyl groups can be saturated or have different degrees of unsaturation.
[0138] Preferably, the PEG-DAA conjugate is PEG-didecyloxypropyl (C 10 ) complex, PEG-dilauryloxypropyl (C 12 ) conjugate, PEG-dimyristyloxypropyl (C 14 ) conjugate, PEG-dipalmityloxypropyl (C 16 ) complex, or PEG-distearyloxypropyl (C 18 ) conjugates. In these embodiments, the PEG preferably has an average molecular weight of 750 or 2,000 daltons. In certain embodiments, the terminal hydroxyl groups of the PEG are replaced with methyl groups.
[0139] In addition to the above, other hydrophilic polymers can be used instead of PEG. Examples of suitable polymers that can be used instead of PEG include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.
[0140] In some embodiments, the lipid conjugates (e.g., PEG-lipid) comprise 0.1 mol% to 2 mol%, 0.5 mol% to 2 mol%, 1 mol% to 2 mol%, 0.6 mol% to 1.9 mol%, 0.7 mol% to 1.8 mol%, 0.8 mol% to 1.7 mol%, 0.9 mol% to 1.6 mol%, 0.9 mol% to 1.8 mol%, 1 mol% to 1.8 mol%, 1 mol% to 1.7 mol%, 1.2 mol% to 1.8 mol%, 1.2 mol% to 1.7 mol%, 1.3 mol% to 1.6 mol%, or 1.4 mol% to 1.5 mol% (or any percentage or range thereof) of the total lipid present in the particle. In other embodiments, the lipid conjugate (e.g., PEG-lipid) comprises 0 mol% to 20 mol%, 0.5 mol% to 20 mol%, 2 mol% to 20 mol%, 1.5 mol% to 18 mol%, 2 mol% to 15 mol%, 4 mol% to 15 mol%, 2 mol% to 12 mol%, 5 mol% to 12 mol%, or 2 mol% (or any percentage or range thereof) of the total lipid present in the particle.
[0141] In further embodiments, the lipid conjugate (e.g., PEG-lipid) comprises 4 mol% to 10 mol%, 5 mol% to 10 mol%, 5 mol% to 9 mol%, 5 mol% to 8 mol%, 6 mol% to 9 mol%, 6 mol% to 8 mol%, or 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any percentage or range thereof) of the total lipid present in the particle.
[0142] The percentage of lipid conjugate (e.g., PEG-lipid) present in the lipid particles of the present invention is a target amount, and the actual amount of lipid conjugate present in the formulation can vary, for example, by ±2 mol %. One of skill in the art will appreciate that the concentration of Lipid-conjugates may vary depending on the rate at which the Lipid-conjugates and lipid particles used become fusogenic.
[0143] By controlling the composition and concentration of the lipid complexes, the rate at which the lipid complexes exchange out of the lipid particle, as well as the rate at which the lipid particle becomes fusogenic, can be controlled.In addition, other variables, including, for example, pH, temperature, or ionic strength, can be used to vary and / or control the rate at which the lipid particle becomes fusogenic.Other methods that can be used to control the rate at which the lipid particle becomes fusogenic will be apparent to those skilled in the art upon reading this disclosure.In addition, by controlling the composition and concentration of the lipid complexes, the lipid particle size can be controlled.
[0144] Compositions and Formulations for Administration
[0145] The nucleic acid-lipid composition of the present disclosure can be administered by various routes, for example, to effect systemic delivery via intravenous, parenteral, intraperitoneal, or topical routes.In some embodiments, siRNA can be delivered intracellularly, for example, to cells of target tissues such as lung or liver, or inflamed tissue.In some embodiments, the present disclosure provides a method for delivering siRNA in vivo.The nucleic acid-lipid composition can be administered intravenously, subcutaneously, or intraperitoneally to a subject.In some embodiments, the present disclosure provides a method for the in vivo delivery of interfering RNA to the lungs of a mammalian subject.
[0146] In some embodiments, the present disclosure provides a method for treating a disease or disorder in a mammalian subject.A therapeutically effective amount of the composition of the present disclosure, which comprises a nucleus, a cationic lipid, an amphiphile, a phospholipid, cholesterol, and a PEG-linked cholesterol, can be administered to a subject having a disease or disorder associated with the expression or overexpression of a gene that can be reduced, decreased, downregulated, or silenced by the composition.
[0147] The compositions and methods of the present disclosure may be administered to a subject by a variety of mucosal administration modes, including oral, rectal, vaginal, intranasal, intrapulmonary, or transdermal or transcutaneous delivery, or topical delivery to the eye, ear, skin, or other mucosal surface. In some aspects of the present disclosure, the mucosal tissue layer comprises an epithelial cell layer. The epithelial cells may be pulmonary, tracheal, bronchial, alveolar, nasal, buccal, epidermal, or gastrointestinal. The compositions of the present disclosure may be administered using conventional actuators, such as mechanical spray devices, as well as pressurized, electrically actuated, or other types of actuators.
[0148] The compositions of the present disclosure may be administered in aqueous solution as a nasal or pulmonary spray, or may be dispensed in spray form by various methods known to those skilled in the art. Pulmonary delivery of the compositions of the present disclosure is accomplished by administering the compositions in the form of drops, particles, or sprays, which may be aerosolized, nebulized, or atomized, for example. The particles of the composition, spray, or aerosol may be in either liquid or solid form. A preferred system for dispensing liquids as nasal sprays is disclosed in U.S. Pat. No. 4,511,069. Such formulations can be conveniently prepared by dissolving the compositions according to the present disclosure in water to produce an aqueous solution, and sterilizing this solution. The formulations may be presented in a multi-dose container, for example in a sealed dispensing system as disclosed in U.S. Pat. No. 4,511,069. Other suitable nasal spray delivery systems include the TRANSDERMAL SYSTEMIC SYSTEM. MEDICATION, YW Hien ed., Elsevier Publishers, New York, 1985, and U.S. Patent No. 4,778,810. Additional aerosol delivery forms can include, for example, compressed air, jet, ultrasonic, and piezoelectric nebulizers, which deliver biologically active agents dissolved or suspended in a pharmaceutical solvent, such as water, ethanol, or mixtures thereof.
[0149] The nasal and pulmonary spray solutions of the present disclosure typically include the drug or drugs to be delivered, optionally formulated with a surface active agent, such as a non-ionic surfactant (e.g., polysorbate-80) and one or more buffers. In some embodiments of the present disclosure, the nasal spray solution further includes a propellant. The pH of the nasal spray solution may be pH 6.8 to 7.2. The pharmaceutical solvent used may also be a slightly acidic aqueous buffer with a pH of 4 to 6. Other components may be added to enhance or maintain chemical stability, including preservatives, surfactants, dispersants, or gases.
[0150] In some embodiments, the present disclosure is a pharmaceutical product comprising a solution containing a composition of the present disclosure and an actuator for a pulmonary, mucosal, or intranasal spray or aerosol.
[0151] The dosage form of the composition of the present disclosure may be a liquid in the form of droplets or an emulsion, or in the form of an aerosol.
[0152] The dosage form of the composition of the present disclosure may be a solid that can be reconstituted in a liquid prior to administration. The solid may be administered as a powder. The solid may be in the form of a capsule, tablet, or gel.
[0153] To formulate a pulmonary delivery composition within the present disclosure, the biologically active agent can be combined with various pharma- ceutically acceptable additives, as well as bases or carriers for dispersing the active agent(s). Examples of additives include pH adjusters, such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid, and mixtures thereof. Other additives include local anesthetics (e.g., benzyl alcohol), isotonicity agents (e.g., sodium chloride, mannitol, sorbitol), adsorption inhibitors (e.g., Tween 80), solubility enhancers (e.g., cyclodextrin and its derivatives), stabilizers (e.g., serum albumin), and reducing agents (e.g., glutathione). When the mucosal delivery composition is liquid, the tonicity of the formulation is typically adjusted to a value that does not cause substantial irreversible tissue damage in the mucosa at the administration site, as measured relative to the tonicity of 0.9% (w / v) saline, which is considered to be 1. Generally, the tonicity of the solution is adjusted to a value of 1 / 3 to 3, more typically 1 / 2 to 2, and most often 3 / 4 to 1.7.
[0154] The biologically active agent may be dispersed in a base or vehicle, which may include a hydrophilic compound capable of dispersing the active agent and any desired additives. The base may be selected from a wide range of suitable carriers, including, but not limited to, copolymers of polycarboxylic acids or their salts, copolymers of carboxylic anhydrides (e.g., maleic anhydride) with other monomers (e.g., methyl (meth)acrylate, acrylic acid, etc.), hydrophilic vinyl polymers, such as polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, cellulose derivatives, such as hydroxymethylcellulose, hydroxypropylcellulose, and natural polymers, such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid, and non-toxic metal salts thereof. In many cases, biodegradable polymers, such as polylactic acid, poly(lactic acid-glycolic acid) copolymers, polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymers, and mixtures thereof, are selected as the base or carrier. Alternatively or in addition, synthetic fatty acid esters, such as polyglycerin fatty acid esters, sucrose fatty acid esters, and the like, may be used as carriers. Hydrophilic polymers and other carriers can be used alone or in combination and can impart enhanced structural integrity to the carrier by partial crystallization, ionic bonding, crosslinking, etc. Carriers can be provided in a variety of forms including fluid or viscous solutions, gels, pastes, powders, microspheres, and films for direct application to the nasal mucosa. Use of selected carriers in this context can result in enhanced absorption of the biologically active agent.
[0155] Formulations for mucosal, nasal, or pulmonary delivery may contain hydrophilic low molecular weight compounds as bases or excipients. Such hydrophilic low molecular weight compounds provide a medium through which water-soluble active agents, such as physiologically active peptides or proteins, can diffuse through the base to the body surface where the active agent is absorbed. The hydrophilic low molecular weight compounds optionally absorb moisture from the mucosa or administration atmosphere to dissolve the water-soluble active peptide. The molecular weight of the hydrophilic low molecular weight compounds is generally 10,000 or less, preferably 3,000 or less. Examples of hydrophilic low molecular weight compounds include polyol compounds such as oligosaccharides, disaccharides, and monosaccharides, including sucrose, mannitol, lactose, L-arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, D-galactose, lactulose, cellobiose, gentibiose, glycerin, polyethylene glycol, and mixtures thereof. Further examples of hydrophilic low molecular weight compounds include N-methylpyrrolidone, alcohols (eg, oligovinyl alcohol, ethanol, ethylene glycol, propylene glycol, etc.), and mixtures thereof.
[0156] The compositions of the present disclosure may alternatively contain pharma- ceutically acceptable substances as carriers necessary to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, and wetting agents, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, and mixtures thereof. For solid compositions, conventional non-toxic pharma-ceutically acceptable carriers can be used, including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
[0157] In certain embodiments of the present disclosure, the biologically active agent may be administered in a time-release formulation, for example, a composition that includes a sustained release polymer. The active agent may be prepared with a carrier that protects against rapid release, for example, a controlled release vehicle, such as a polymer, a microencapsulated delivery system, or a bioadhesive gel. The long-term delivery of the active agent in various compositions of the present disclosure may be achieved by including in the composition an agent that delays absorption, for example, aluminum monooleate hydrogel and gelatin.
[0158] While the present disclosure has been described with respect to certain specific embodiments and numerous details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the present disclosure includes additional embodiments and that some of the details described herein may be substantially modified without departing from the present disclosure. The present disclosure includes such additional embodiments, modifications, and equivalents. In particular, the present disclosure includes any combination of the features, terms, or elements of the various exemplary components and examples. EXAMPLES
[0159] Example 1: Exemplary lipids Exemplary compounds of formula I are provided in Table 1. The structures of the compounds are shown in the first column. The designations of the compounds are given according to formula I. [ka] The first number pair indicates the number of carbons in the ester including the carbonyl for L1 and L2, the number pair in parentheses indicates the number of carbons in each branch of the branched alkyl R1, or R1 / R2 (stars indicate double bonds) if R2 is also branched, the number of carbons in R3 is indicated, and the last line indicates the substitution of R4 and R5. ATX numbers are shown for reference purposes herein. Calculated LogD values (c-LogD) and calculated pKa (c-pKa) values are shown, as well as the measured pKa (measured in the formulation environment) in parentheses. c-LogD and c-pKa values are generated by ACD Labs Structure Designer v12.0. Biological activity is the in vivo factor VII knockdown percentage at a dose of 0.03 mg / kg unless otherwise specified. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12]
[0160] Example 2: Synthesis of ATX-0043
[0161] FIG. 1 shows the synthetic route to ATX-0043, which is further described below.
[0162] ATX-0043: Process 1 [ka]
[0163] A 500 mL single-neck round-bottom flask was charged with 25 g of hexanoic acid (SM1; 1 eq.) dissolved in dichloromethane (DCM; 200 mL), then 27.6 mL of oxalyl chloride (1.5 eq.) was added slowly at 0° C. with stirring under nitrogen atmosphere, followed by 0.5 mL of dimethylformamide (DMF; catalyst). The resulting reaction mixture was stirred at room temperature for 2 hours.
[0164] In a separate 1-liter two-neck round-bottom flask, 31.4 g of N,O-dimethylhydroxylamine hydrochloride (1.5 eq.) in DCM (200 mL) was added with an addition funnel of 89.8 mL of triethylamine (Et3N, 3 eq.) stirred at 0° C. After concentrating under reduced pressure, the acid chloride was added dropwise over 20 min with an addition funnel by dissolving it in DCM (100 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature under nitrogen atmosphere for 3 h.
[0165] The progress of the reaction was monitored by thin layer chromatography (TLC) (20% ethyl acetate (EtOAc) / hexane; Rf: 0.5). The reaction mass was diluted with water (300 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure.
[0166] The crude compound was subjected to column chromatography using (60-120 silica gel; 10% EtOAc / Hexanes). Yield: 20.0 g; Yield: 58%.
[0167] ATX-0043: Process 2 [ka]
[0168] To a solution of 33 g of pentylmagnesium bromide (1.5 eq.) in tetrahydrofuran (THF; 100 mL) placed in a 500 mL two-neck round-bottom flask and stirred at 0° C. under a nitrogen atmosphere, a solution of 20 g of N-methoxy-N-methylhexanamide (1 eq.) (dissolved in 200 mL of THF) was added and the resulting reaction mixture was stirred at room temperature for 4 h.
[0169] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (150 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure.
[0170] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% EtOAc / Hexanes). Yield: 15.0 g; Yield: 66%.
[0171] ATX-0043: Process 3 [ka]
[0172] To a solution of 15 g of undecan-6-one (1 eq.) dissolved in 25 mL of methanol (MeOH) in 150 mL of THF was added 4.9 g of sodium borohydride (1.5 eq.) at 0° C., and the resulting solution was stirred at room temperature for 2 hours.
[0173] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (100 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (150 mL) and water (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 14.0 g; 93%.
[0174] ATX-0043: Process 4 [ka]
[0175] To a solution of 15 g of 4-aminobutanoic acid (1 eq.) dissolved in 150 mL of THF was added 145 mL of aqueous 1 N NaOH solution (1 eq.) followed by 43.4 mL of Boc anhydride (1.3 eq.) sequentially over 15 min each using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 h.
[0176] The progress of the reaction was monitored by TLC (10% MeOH in chloroform (CHCl3); Rf: 0.5). The reaction mass was quenched with 5% HCl (150 mL) followed by addition of EtOAc (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 20.0 g; Yield 68%.
[0177] ATX-0043: Process 5 [ka]
[0178] To a solution of 12 g of 4-((tert-butoxycarbonyl)amino)butanoic acid (1 eq.) dissolved in DCM (200 mL) and cooled below 0° C., 14.7 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).HCl (1.3 eq.), 10.6 mL of Et3N (1.3 eq.), and 0.72 g of 4-dimethylaminopyridine (DMAP; 0.1 eq.) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, alcohol was added at the same temperature by dissolving in DCM (50 mL) using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0179] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with water (100 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×50 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then extracted with EtOAc (2×50 mL). The organic layers were concentrated under reduced pressure and taken forward crude. Yield 8.5 g; 48%.
[0180] ATX-0043: Process 6 [ka]
[0181] To a solution of 8.5 g of undecan-6-yl 4-((tert-butoxycarbonyl)amino)butanoate (1 eq.) dissolved in 70 mL of DCM was added trifluoroacetic acid (TFA; 10 eq.) at 0° C. and stirred at room temperature for 4 h under a nitrogen atmosphere.
[0182] The progress of the reaction was monitored by TLC (70% EtOAc / Hexane; Rf: 0.2). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then extracted with EtOAc (2 x 100 mL). The organic layer was separated and concentrated under reduced pressure.
[0183] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield: 5.0 g; 33% (based on alcohol).
[0184] ATX-0043: Process 7 [ka]
[0185] To a solution of 14 g of 4-bromobutyric acid (1 equiv.) dissolved in DCM (100 mL) and cooled below 0° C., 21 g of EDC.HCl (1.3 equiv.), 15.2 mL of Et3N (1.3 equiv.), and 1 g of DMAP (0.1 equiv.) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 8.3 g of (Z)-non-2-en-1-ol (0.7 equiv.) was added by dissolving in 50 mL of DCM using an addition funnel and stirred at room temperature for 16 h under nitrogen atmosphere.
[0186] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (50 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×50 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then extracted with EtOAc (2×50 mL). The organic layer was separated and concentrated under reduced pressure.
[0187] The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexanes. Yield: 11.0 g; Yield: 64%.
[0188] ATX-0043: Process 8 [ka]
[0189] To a 250 mL round bottom flask was added 2 g of undecane-6-yl 4-aminobutanoate (1 eq.) and 2.2 g of (Z)-non-2-en-1-yl 4-bromobutanoate (1 eq.), 1.2 g of potassium carbonate (1.2 eq.) in DMF, and the resulting mixture was refluxed at 90° C. for 4 hours under nitrogen atmosphere.
[0190] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). Ice water was added to the reaction mass, which was then extracted with EtOAc, dried over sodium sulfate and concentrated under reduced pressure.
[0191] The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 15% EtOAc / Hexanes. The starting amine and bromo compound were recovered. Yield 1.45 g; 40%.
[0192] ATX-0043: Process 9 [ka]
[0193] To a solution of 1.45 g of (Z)-non-2-en-1-yl 4-((4-oxo-4-(undecan-6-yloxy)butyl)amino)butanoate (1 eq.) dissolved in dry DCM, 1.29 mL of triethylamine (3 eq.) and 360 mg of triphosgene (0.4 eq.) were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 h under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0194] To 360 mg of sodium hydride (5.5 eq.) dissolved in dry THF (20 mL) in a two-necked 250 mL round bottom flask stirred at 0° C. under nitrogen atmosphere, 2.1 g of 2-(dimethylamino)ethane-1-thiol hydrochloride (5.5 eq.) in THF (30 mL) was added and stirring was continued for 5 min under nitrogen atmosphere. The above carbonyl chloride dissolved in THF (50 mL) was added slowly over about 15 min using an addition funnel and stirred at room temperature for 1 h.
[0195] The reaction mass was quenched with saturated NH4Cl solution (20 mL) followed by addition of EtOAc (20 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 20 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography. The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char).
[0196] Purification was carried out using silica gel (100-200 mesh; 18% EtOAc / Hexanes) chromatography. Yield: 500 mg; Yield: 26%. 1 Confirmed by 1 H NMR; HPLC; and Mass Spectrometry (mass).
[0197] ATX-0043 / RL-43A: 1 H-NMR(PPM,400MHz,CDCl3):δ=5.63(m,1),5.54(m,1),4.87(m,1),4.63(d,J=7.0,2),3.37(brs,4),3.03(t,J= 7.0,2),2.27(s,6),2.22~2.32(4),2.09(m,2),1.80~1.90(4),1.45~1.55(4),1.20~1.40(22),0.83~0.92(9). Example 3: Synthesis of ATX-0057
[0198] FIG. 2 shows the synthetic route to ATX-0057, which is further described below.
[0199] ATX-0057: Step 1: N-Methoxy-N-methyloctamide [ka]
[0200] A 2-liter two-neck round-bottom flask was charged with octanoic acid (1 eq.) dissolved in DCM (300 mL), then 1.5 eq. of oxalyl chloride was added slowly at 0° C. under nitrogen atmosphere with stirring. The resulting reaction mixture was stirred at room temperature for 2 hours. In a separate 2-liter two-neck round-bottom flask, 2 eq. of N,O-dimethylhydroxylamine hydrochloride in DCM (200 mL) was added with an addition funnel with 3 eq. of trimethylamine stirred at 0° C. After concentrating under reduced pressure, the resulting solution was added dropwise over 20 minutes using an addition funnel by dissolving in DCM (150 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature for 3 hours under nitrogen atmosphere.
[0201] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexane). Yield 85 g; 65%.
[0202] ATX-0057: Step 2: Hexadecane-8-one [ka]
[0203] To a solution of octylmagnesium bromide in THF (100 mL) placed in a 1 L, two-necked, round-bottom flask stirred at 0° C. under a nitrogen atmosphere was added the N-methoxy-N-methyloctanamide solution (dissolved in 200 mL of THF) and the resulting reaction mixture was stirred at room temperature for 4 h.
[0204] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (250 mL) followed by addition of EtOAc (350 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% EtOAc / hexanes). Yield 65 g; 63%.
[0205] ATX-0057: Step 3: Hexadecane-8-ol [ka]
[0206] To a solution of hexadecan-8-one (1 eq) in MeOH / THF at 0° C. was added 1 eq of sodium borohydride and the resulting solution was stirred at room temperature for 1.5 h.
[0207] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5 ). The reaction mass was quenched with saturated NH4Cl solution (75 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3×100 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 60 g; 91%.
[0208] ATX-0057: Step 4: 4-((tert-butoxycarbonyl)amino)butanoic acid [ka]
[0209] To a solution of 4-aminobutanoic acid in THF was added aqueous 1N NaOH solution followed by Boc anhydride sequentially over 15 minutes using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0210] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (250 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 150 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 80 g; Yield 81%.
[0211] ATX-0057: Step 5: Hexadecan-8-yl 4-((tert-butoxycarbonyl)amino)butanoate [ka]
[0212] To a solution of 4-((tert-butoxycarbonyl)amino)butanoic acid dissolved in DCM (200 mL) and cooled below 0° C., EDC.HCl, Et3N, and 4-dimethylaminopyridine (DMAP) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 1 equivalent of hexadecan-8-ol alcohol was added at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0213] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then EtOAc (200 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude to next step. Yield 80 g (crude; required compound and alcohol).
[0214] ATX-0057: Step 6: Hexadecan-8-yl 4-aminobutanoate [ka]
[0215] To a solution of hexadecan-8-yl-4-((tert-butoxycarbonyl)amino)butanoate in DCM was added TFA at 0° C. and incubated at room temperature for 3 h under nitrogen atmosphere. The mixture was stirred. The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (300 mL) and then extracted with EtOAc (2 x 200 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield 40 g; 59% for two steps; confirmed by mass.
[0216] ATX-0057: Step 7: (Z)-Non-2-en-1-yl 4-bromobutanoate [ka]
[0217] To a solution of 4-bromobutyric acid dissolved in DCM (400 mL) and cooled below 0° C., EDC.HCl, Et3N, and DMAP were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution was added (Z)-non-2-en-1-ol by dissolving in 100 mL of DCM using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0218] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (300 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×150 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (200 mL) and then extracted with EtOAc (150 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexanes. The alcohol was recovered. Yield 27 g; 51%.
[0219] ATX-0057: Step 8: Hexadecan-8-yl (Z)-4-((4-(non-2-en-1-yloxy)-4-oxobutyl)amino)butanoate [ka]
[0220] To a solution of hexadecan-8-yl 4-aminobutanoate, (Z)-non-2-en-1-yl 4-bromobutanoate in acetonitrile (ACN) was added potassium carbonate and the resulting mixture was refluxed at 90° C. for 4 h under nitrogen atmosphere. The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (20 mL) and the filtrate was concentrated under reduced pressure. The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 15% EtOAc / Hexane. The starting amine and bromo compounds were recovered. Yield 20 g; 40%; confirmed by mass.
[0221] ATX-0057: Process 9 [ka]
[0222] To a solution of hexadecan-8-yl (Z)-4-((4-(non-2-en-1-yloxy)-4-oxobutyl)amino)butanoate dissolved in dry DCM, trimethylamine and triphosgene were added at 0° C. in 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 hour under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0223] 2-(Dimethylamino)propane-1-thiol hydrochloride was added to sodium hydride dissolved in dry THF (50 mL) in a two-necked 100 mL round bottom flask stirred at 0° C. under nitrogen atmosphere and stirring was continued for 5 minutes under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (80 mL) was added slowly via syringe over a period of about 10 minutes. The resulting solution was stirred at room temperature under nitrogen atmosphere for 6 hours.
[0224] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (75 mL) followed by addition of EtOAc (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0225] The first purification was performed using silica gel (60-120 mesh). 22 g of crude compound was adsorbed onto 60 g of silica gel and poured onto 500 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. 7.5 g of crude compound was adsorbed onto 18 g of neutral alumina and the resultant was poured onto 130 g of neutral alumina in a column. The compound was eluted with 10% EtOAc / Hexane. Yield 29%; 1 Confirmed by 1 H NMR, HPLC and mass.
[0226] ATX-0057 / RL-43C: 1 H-NMR(PPM,400MHz,CDCl3):δ=5.63(m,1),5.51(m,1),4.68(m,1),4.83(d,J=7.0,2) ,3.19(brs,4),3.22(m,2),2.52(m,2),2.23~2.37(4),2.18(s,6),2.08(m,2),1.84~ 1.93(4), 1.46–1.54(4), 1.20–1.40(30), 0.83–0.91(9). Example 4: Synthesis of ATX-0058
[0227] FIG. 3 shows a synthetic route to ATX-0058, which is further described below.
[0228] ATX-0058: Process 1 [ka]
[0229] In a 500 mL two-neck round bottom flask under N2 atmosphere, 30 g of 8-bromooctanoic acid (1 eq.) dissolved in 200 mL of DCM was placed and then slowly added to 26.7 mL of oxalyl chloride (1.5 eq.) at 0° C. with stirring under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 2 h.
[0230] In a separate 1-liter two-neck round-bottom flask, 40.5 g of N,O-dimethylhydroxylamine hydrochloride (2 eq.) in 300 mL of DCM was added to 87 mL of trimethylamine (3 eq.) stirred at 0° C. To the resulting solution, after concentration under reduced pressure, the above acid chloride was added dropwise over 15 minutes using an addition funnel by dissolving it in 500 mL of DCM. The resulting reaction solution was stirred at room temperature for 3 hours under nitrogen atmosphere.
[0231] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (300 mL). The organic layer was separated and the aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure.
[0232] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexanes). Yield 28 g.
[0233] ATX-0058: Process 2 [ka]
[0234] To a solution of 28 g of hexylmagnesium bromide (1 eq.) in THF (100 mL) stirred at 0° C. under a nitrogen atmosphere was added 36.8 g of N-methoxy-N-methyloctanamide (1.3 eq.) in 200 mL of THF, and the resulting reaction mixture was stirred at room temperature for 5 h.
[0235] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure.
[0236] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% ethyl acetate / hexanes). Yield: 24 g; Yield: 77%.
[0237] ATX-0058: Process 3 [ka]
[0238] To a solution of 24 g of tetradecan-7-one (1 eq.) in MeOH / THF was added 4.27 g of sodium borohydride (1 eq.) at 0° C. and the resulting solution was stirred at room temperature for 1 h.
[0239] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (50 mL). Methanol was reduced under reduced pressure. The crude obtained was partitioned between EtOAc (200 mL) and water. The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 80 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 21.5 g; 89%.
[0240] ATX-0058: Process 4 [ka]
[0241] To a solution of 20 g of 4-aminobutanoic acid dissolved in 140 mL of THF was added 196 mL of aqueous 1N NaOH solution followed by 36.8 g of Boc anhydride using a funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0242] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (100 mL) followed by addition of EtOAc (200 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 30 g; 76%.
[0243] ATX-0058: Process 5 [ka]
[0244] To a solution of 10 g of 4-((tert-butoxycarbonyl)amino)butanoic acid (1 eq.) dissolved in DCM (150 mL) and cooled below 0° C., 12.2 g of EDC.HCl (1.3 eq.), 20.4 mL of Et3N (3 eq.), and 488 mg of DMAP (0.1 eq.) were added sequentially at 10 min intervals. To this resulting solution, the alcohol was added by dissolving in DCM using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0245] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mass was quenched with water (100 mL) and the organic layer was separated. The aqueous layer was washed with DCM (2×50 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution and EtOAc (100 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude. Yield 12.7 g (crude).
[0246] ATX-0058: Process 6 [ka]
[0247] To a solution of 12.5 g of tetradecan-7-yl 4-((tert-butoxycarbonyl)amino)butanoate (1 eq.) dissolved in 100 mL of DCM was added 23.9 mL of TFA (10 eq.) at 0° C. and stirred at room temperature for 3 h under nitrogen atmosphere.
[0248] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and EtOAc (100 mL) was added. The organic layer was separated and concentrated under reduced pressure.
[0249] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3) to recover the alcohol. 7 g in two steps; 47% yield; confirmed by mass.
[0250] ATX-0058: Process 7 [ka]
[0251] To a solution of 20 g of 4-bromobutyric acid (1 eq.) dissolved in DCM (150 mL) and cooled to 0° C., 1.5 eq. of EDC.HCl, 3 eq. of Et3N, and 0.1 eq. of DMAP were added sequentially at 10 min intervals. To this resulting solution, 0.7 eq. of (Z)-non-2-en-1-ol was added by dissolving in 100 mL of DCM using a funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0252] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.7). The reaction mass was quenched with water (100 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution and EtOAc (150 mL) was added. The organic layer was separated and concentrated under reduced pressure.
[0253] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 5% EtOAc / Hexanes). Yield: 17 g; Yield: 69%. 1 Confirmed by H NMR.
[0254] ATX-0058: Process 8 [ka]
[0255] To a solution of 6 g of tetradecan-7-yl 4-aminobutanoate (1 eq.), 5.8 g of (Z)-non-2-en-1-yl 4-bromobutanoate (1 eq.) in ACN (125 mL) was added 2.7 g of potassium carbonate (1.2 eq.) and the resultant was refluxed at 90° C. for 3 h under nitrogen atmosphere.
[0256] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5). The reaction mass was filtered and the filtrate was concentrated under reduced pressure.
[0257] The crude compound was subjected to column chromatography using (100-200 mesh silica gel; 15% EtOAc / Hexanes). Yield 4.5 g; Yield 44%; confirmed by mass.
[0258] ATX-0058: Process 9 [ka]
[0259] To a solution of 4.4 g of (Z)-non-2-en-1-yl 4-((4-oxo-4-(tetradecan-7-yloxy)butyl)amino)butanoate (1 eq.) dissolved in 30 mL of dry DCM, 0.83 mL of trimethylamine (3 eq.) and 418 mg of triphosgene (0.5 eq.) were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 h under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0260] To 192 mg of sodium hydride (10 eq.) dissolved in dry THF (25 mL) in a two-neck 100 mL round bottom flask was added 564 mg of 2-(dimethylamino)propane-1-thiol hydrochloride (5 eq.) at 0° C. and stirring was continued for 5 min under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (35 mL) was slowly added via syringe over a period of about 10 min. The resulting solution was stirred at room temperature under nitrogen atmosphere for 4 h.
[0261] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl (30 mL) followed by addition of EtOAc (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 50 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0262] The first purification was performed using silica gel (60-120 mesh). 5.0 g of crude compound was adsorbed onto 9 g of silica gel and poured onto 90 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexanes. The second purification was performed using neutral alumina with HPLC grade solvents. 1.5 g of crude compound was adsorbed onto 4 g of neutral alumina. The mixture was poured onto a column of 40 g neutral alumina. The compound was eluted with 10% EtOAc / Hexane. Yield: 1.2 g; Yield: 21%. 1 Confirmed by H NMR; HPLC; Mass.
[0263] ATX-0058 / RL-43B: 1 H-NMR(PPM,400MHz,CDCl3):δ=5.65(m,1),5.52(m,1),4.86(m,1),4.63(d,J=7.0,2),3.37(brs,4),3.02(t,J=6.0,2),2 .53(t,J=6.0,2),2.27~2.36(4),2.27(s,6),2.09(m,2),1.83~1.96(4),1.46~1.54(4),1.20~1.40(26),0.84~0.91(9). Example 5: Synthesis of ATX-0081
[0264] FIG. 4 shows the synthetic route to ATX-0081, which is further described below.
[0265] ATX-0081: Process 1 [ka]
[0266] A 2-liter two-neck round-bottom flask was charged with octanoic acid dissolved in DCM (200 mL), then 1.5 equivalents of oxalyl chloride was added slowly at 0° C. with stirring under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 2 hours. In a separate 2-liter two-neck round-bottom flask, 2 equivalents of N,O-dimethylhydroxylamine hydrochloride in DCM (200 mL) was added with an addition funnel with stirring at 0° C. The resulting solution was concentrated under reduced pressure, and then the above acid chloride was added dropwise over 20 minutes with an addition funnel by dissolving it in DCM (150 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature for 3 hours under nitrogen atmosphere.
[0267] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexane). Yield 33 g; 84%.
[0268] ATX-0081: Process 2 [ka]
[0269] To a solution of 22 g of heptylmagnesium bromide (1.5 eq.) in THF (100 mL) placed in a 1 L two-neck round bottom flask stirred at 0° C. under nitrogen atmosphere was added a solution of N-methoxy-N-methyloctanamide (1 eq.) (dissolved in 200 mL of THF) and the resulting reaction mixture was stirred at room temperature for 4 h.
[0270] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (250 mL) followed by EtOAc (35 0 mL) was added. The organic layer was separated and the aqueous layer was washed with EtOAc (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% EtOAc / Hexane). Yield 22 g; 65%.
[0271] ATX-0081: Process 3 [ka]
[0272] To a solution of 22 g of pentadecan-8-one (1 eq.) in MeOH / THF was added 1.5 eq. of sodium borohydride at 0° C. and the resulting solution was stirred at room temperature for 1 h.
[0273] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (75 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 20 g; 90%.
[0274] ATX-0081: Process 4 [ka]
[0275] To a solution of 50 g of 4-aminobutanoic acid dissolved in 350 mL of THF was added 490 mL of aqueous 1N NaOH solution followed by 140 mL of Boc anhydride sequentially over 15 minutes using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0276] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (250 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 150 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 80 g; Yield 81%.
[0277] ATX-0081: Process 5 [ka]
[0278] To a solution of 10 g of 4-((tert-butoxycarbonyl)amino)butanoic acid dissolved in DCM (250 mL) and cooled below 0° C., 1.3 equivalents of EDC.HCl, Et3N, and 4-dimethylaminopyridine (DMAP) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 1 equivalent of pentadecan-7-ol alcohol was added at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0279] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5 ). The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then EtOAc (200 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude to next step. Yield 8.5 g (crude; required compound and alcohol).
[0280] ATX-0081: Process 6 [ka]
[0281] To a solution of 8.5 g of pentadecan-8-yl 4-((tert-butoxycarbonyl)amino)butanoate in 65 mL of DCM was added 10 equivalents of TFA at 0° C. and stirred at room temperature for 3 hours under nitrogen atmosphere.
[0282] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (300 mL) and then extracted with EtOAc (2 x 200 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Production 4 g in two steps; Yield 25%; confirmed by mass.
[0283] ATX-0081: Process 7 [ka]
[0284] To a solution of 4-bromobutyric acid dissolved in DCM (300 mL) and cooled below 0° C., EDC.HCl, Et3N, and DMAP were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 20 g of (Z)-non-2-en-1-ol was added by dissolving in 100 mL of DCM using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0285] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (300 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×150 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (200 mL) and then extracted with EtOAc (150 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexanes. The alcohol was recovered. Yield 19 g; 55%.
[0286] ATX-0081: Process 8 [ka]
[0287] To a solution of 4.5 g of pentadecan-8-yl 4-aminobutanoate, 1 equivalent of (Z)-non-2-en-1-yl 4-bromobutanoate in 70 mL of acetonitrile (ACN), 1.4 equivalents of potassium carbonate were added and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0288] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (20 mL) and the filtrate was concentrated under reduced pressure. The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 15% EtOAc / Hexane. The starting amine and bromo compounds were recovered. Yield 27%; confirmed by mass.
[0289] ATX-0081: Process 9 [ka]
[0290] To a solution of 2.1 g of pentadecan-8-yl (Z)-4-((4-(non-2-en-1-yloxy)-4-oxobutyl)amino)butanoate dissolved in 150 mL of dry DCM, 3 equivalents of triethylamine and triphosgene were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 hour under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0291] To 7 equivalents of sodium hydride dissolved in dry THF (80 mL) in a two-necked 100 mL round bottom flask stirred at 0° C. under nitrogen atmosphere, 3.5 equivalents of 2-(dimethylamino)propane-1-thiol hydrochloride was added and stirring was continued for 5 minutes under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (80 mL) was added slowly via syringe over a period of about 10 minutes. The resulting solution was stirred overnight at 0° C. to room temperature under nitrogen atmosphere. Stirred.
[0292] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (75 mL) followed by addition of EtOAc (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0293] The first purification was performed using silica gel (60-120 mesh). The crude compound was adsorbed onto 60 g of silica gel and poured onto 500 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. The crude compound was adsorbed onto 18 g of neutral alumina and poured onto 130 g of neutral alumina in a column. The compound was eluted with 10% EtOAc / Hexane. Yield 1.5 g; Yield 45%; 1 Confirmed by 1 H NMR, HPLC and mass.
[0294] ATX-0081 / RL-48B: 1 H-NMR(PPM,500MHz,CDCl3):δ=5.64(m,1),5.52(m,1),4.86(m,1),4.63(d,J=7.0,2),3.31~3.44(4),3.02(t,J=7.0,2), 2.52(t,J=7.0,2),2.26~2.36(4),2.27(s,6),2.10(m,2),1.84~1.95(4),1.46~1.54(4),1.20~1.40(26),0.85~0.94(9). Example 6: Synthesis of ATX-0082
[0295] FIG. 5 shows a synthetic route to ATX-0082, which is further described below.
[0296] ATX-0082: Process 1 [ka]
[0297] A 2-liter two-neck round-bottom flask was charged with 30 g of octanoic acid dissolved in DCM (200 mL), then 1.5 equivalents of oxalyl chloride was added slowly at 0° C. with stirring under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 2 hours. In a separate 2-liter two-neck round-bottom flask, 2 equivalents of N,O-dimethylhydroxylamine hydrochloride in DCM (200 mL) was added with an addition funnel with stirring at 0° C. The resulting solution was concentrated under reduced pressure, and then the above acid chloride was added dropwise over 20 minutes with an addition funnel by dissolving it in DCM (150 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature for 3 hours under nitrogen atmosphere.
[0298] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexane). Yield 33 g; 84%.
[0299] ATX-0082: Process 2 [ka]
[0300] To a solution of heptylmagnesium bromide (1.5 equiv.) in THF (100 mL) placed in a 1 L two-neck round bottom flask and stirred at 0° C. under nitrogen atmosphere was added a solution of 28 g of N-methoxy-N-methyloctanamide (1 equiv.) (dissolved in 200 mL of THF) and the resulting reaction mixture was stirred at room temperature for 4 h.
[0301] The progress of the reaction was monitored by TLC (10% EtOAc in hexane; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (250 mL) followed by addition of EtOAc (350 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% EtOAc / hexane). Yield 22 g; 65%.
[0302] ATX-0082: Process 3 [ka]
[0303] To a solution of 22 g of pentadecan-8-one (1 eq.) in MeOH / THF was added 1.5 eq. of sodium borohydride at 0° C. and the resulting solution was stirred at room temperature for 1 h.
[0304] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (75 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 20 g; 90%.
[0305] ATX-0082: Process 4 [ka]
[0306] To a solution of 15 g of 4-aminobutanoic acid dissolved in 120 mL of THF was added 185 mL of aqueous 1N NaOH solution followed by 50 mL of Boc anhydride sequentially over a period of 15 minutes using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0307] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (250 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 150 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 27 g; 85%.
[0308] ATX-0082: Process 5 [ka]
[0309] To a solution of 10 g of 4-((tert-butoxycarbonyl)amino)butanoic acid in DCM (250 mL) and cooled to below 0° C., 1.3 equivalents of EDC.HCl, EtN 、 and 4-dimethylaminopyridine (DMAP) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution was added 1 equivalent of pentadecan-7-ol alcohol at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0310] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then EtOAc (200 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude to next step. Yield 8 g (crude; required compound and alcohol).
[0311] ATX-0082: Process 6 [ka]
[0312] To a solution of 8.0 g of pentadecan-8-yl 4-((tert-butoxycarbonyl)amino)butanoate in 60 mL of DCM was added 10 equivalents of TFA at 0° C. and stirred at room temperature for 3 hours under nitrogen atmosphere.
[0313] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (300 mL) and then extracted with EtOAc (2 x 200 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield 4 g; 25% for two steps; confirmed by mass.
[0314] ATX-0082: Process 7 [ka]
[0315] To a solution of 4-bromobutyric acid dissolved in DCM (400 mL) and cooled below 0° C., 1.5 equivalents of EDC.HCl, 3 equivalents of Et3N, and DMAP were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 20 g of (Z)-non-2-en-1-ol was added by dissolving in 100 mL of DCM using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0316] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (300 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×150 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (200 mL) and then extracted with EtOAc (150 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexanes. The alcohol was recovered. Yield 18 g; 55%.
[0317] ATX-0082: Process 8 [ka]
[0318] To a solution of 4.0 g of pentadecan-8-yl 4-aminobutanoate, 1 equivalent of (Z)-non-2-en-1-yl 4-bromobutanoate in 90 mL of ACN, 1.4 equivalents of potassium carbonate were added and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0319] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (20 mL) and the filtrate was concentrated under reduced pressure. The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 15% EtOAc / Hexane. The starting material (amine and bromo compound) was recovered. Yield 2.2 g; 30%; confirmed by mass.
[0320] ATX-0082: Process 9 [ka]
[0321] To a solution of 2.2 g of pentadecan-8-yl (Z)-4-((4-(non-2-en-1-yloxy)-4-oxobutyl)amino)butanoate dissolved in 25 mL of dry DCM, 3 equivalents of triethylamine and triphosgene were added at 0° C. in 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 h under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0322] To 7 equivalents of sodium hydride dissolved in dry THF (100 mL) in a two-necked 100 mL round bottom flask stirred at 0° C. under nitrogen atmosphere, 3.5 equivalents of 2-(dimethylamino)propane-1-thiol hydrochloride was added and stirring continued for 5 minutes under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (100 mL) was slowly added via syringe over a period of about 10 minutes. The resulting solution was stirred overnight at 0° C. to room temperature under nitrogen atmosphere.
[0323] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (75 mL) followed by addition of EtOAc (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0324] The first purification was performed using silica gel (60-120 mesh). The crude compound was adsorbed onto 60 g of silica gel and poured onto 500 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. The crude compound was adsorbed onto 18 g of neutral alumina and poured onto 130 g of neutral alumina in a column. The compound was eluted with 10% EtOAc / Hexane. Yield 1.2 g; Yield 43%; 1 Confirmed by 1 H NMR, HPLC and mass.
[0325] ATX-0082 / RL-47A: 1 H-NMR(PPM,500MHz,CDCl3):δ=5.64(m,1),5.52(m,1),4.87(m,1),4.62(d,J=7.0,2),3.61(t,J=7.0,2),3.28~3.37(2),3.02( t,J=7.0,2),2.61(m,2),2.52(t,J=7.0,2),2.31(m,2),2.27(s,6),2.10(m,2),1.62~1.70(6),1.21~1.40(32),0.85~0.91(9). Example 7: Synthesis of ATX-0086
[0326] FIG. 6 shows the synthetic route to ATX-0086, which is further described below.
[0327] ATX-0086: Process 1 [ka]
[0328] A 2-liter, two-necked round-bottom flask was charged with 30 g of octanoic acid dissolved in DCM (200 mL) and then 1.5 equivalents of oxalyl chloride was added slowly at 0° C. with stirring under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 2 hours. In a separate 2-liter, two-necked round-bottom flask, 2 equivalents of N,O-dimethylhydroxylamine hydrochloride in DCM (200 mL) was added with an addition funnel with 3 equivalents of trimethylamine stirred at 0° C. After concentrating under reduced pressure, the acid chloride was added dropwise over 20 min using an addition funnel by dissolving it in DCM (150 mL) under nitrogen atmosphere. The reaction solution was stirred at room temperature under nitrogen atmosphere for 3 h.
[0329] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexane). Yield 38 g; 84%; confirmed by mass.
[0330] ATX-0086: Process 2 [ka]
[0331] To a solution of hexylmagnesium bromide (1.5 equiv.) in THF (100 mL) placed in a 1 L, two-necked, round-bottom flask stirred at 0° C. under a nitrogen atmosphere was added a solution of 38 g of N-methoxy-N-methyloctanamide (1 equiv.) (dissolved in 200 mL of THF) and the resulting reaction mixture was stirred at room temperature for 4 h.
[0332] The progress of the reaction was monitored by TLC (10% EtOAc in hexane; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (250 mL) followed by addition of EtOAc (350 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2x100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% EtOAc / hexane). Yield 44 g; 65%; confirmed by mass.
[0333] ATX-0086: Process 3 [ka]
[0334] To a solution of 44 g of tridecan-7-one (1 eq.) in MeOH / THF was added 1.5 eq. of sodium borohydride at 0° C. and the resulting solution was stirred at room temperature for 1 h.
[0335] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (75 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 40 g; 90%; confirmed by mass.
[0336] ATX-0086: Process 4 [ka]
[0337] To a solution of 50 g of 4-aminobutanoic acid dissolved in 350 mL of THF was added 490 mL of aqueous 1N NaOH solution followed by 140 mL of Boc anhydride sequentially over 15 minutes using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0338] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (250 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 150 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 80 g; Yield 81%; confirmed by mass.
[0339] ATX-0086: Process 5 [ka]
[0340] To a solution of 10 g of 4-((tert-butoxycarbonyl)amino)butanoic acid in DCM (250 mL) and cooled to below 0° C., 1.3 equivalents of EDC.HCl, EtN 、 and 4-dimethylaminopyridine (DMAP) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution was added 1 equivalent of pentadecan-7-ol alcohol at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0341] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then EtOAc (200 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude to next step. Yield 8 g (crude; required compound and alcohol).
[0342] ATX-0086: Process 6 [ka]
[0343] To a solution of 8.0 g of pentadecan-8-yl 4-((tert-butoxycarbonyl)amino)butanoate in 60 mL of DCM was added 10 equivalents of TFA at 0° C. and stirred at room temperature for 3 hours under nitrogen atmosphere.
[0344] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (300 mL) and then extracted with EtOAc (2 x 200 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield 3.5 g; 52% for two steps; confirmed by mass.
[0345] ATX-0086: Process 7 [ka]
[0346] To a solution of 4-bromobutyric acid dissolved in DCM (400 mL) and cooled below 0° C., 1.5 equivalents of EDC.HCl, 2 equivalents of Et3N, and DMAP were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 20 g of (Z)-non-2-en-1-ol was added by dissolving in 100 mL of DCM using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0347] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (300 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×150 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (200 mL) and then extracted with EtOAc (150 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexanes. The alcohol was recovered. Yield 18 g; 55%.
[0348] ATX-0086: Process 8 [ka]
[0349] To a solution of 4.0 g of tridecan-7-yl 4-aminobutanoate, 1 equivalent of (Z)-non-2-en-1-yl 4-bromobutanoate in 90 mL of ACN, 1.4 equivalents of potassium carbonate were added and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0350] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (20 mL) and the filtrate was concentrated under reduced pressure. The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 15% EtOAc / Hexane. The starting amine and bromo compounds were recovered. Yield 2.2 g; 30%; confirmed by mass.
[0351] ATX-0086: Process 9 [ka]
[0352] To a solution of 2.2 g of tridecan-7-yl (Z)-4-((4-(non-2-en-1-yloxy)-4-oxobutyl)amino)butanoate dissolved in 25 mL of dry DCM, 3 equivalents of triethylamine and triphosgene were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 hour under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0353] To 7 equivalents of sodium hydride dissolved in dry THF (100 mL) in a two-necked 100 mL round bottom flask stirred at 0° C. under nitrogen atmosphere, 3.5 equivalents of 2-(dimethylamino)propane-1-thiol hydrochloride was added and stirring continued for 5 minutes under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (100 mL) was slowly added via syringe over a period of about 10 minutes. The resulting solution was stirred overnight at 0° C. to room temperature under nitrogen atmosphere.
[0354] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (75 mL) followed by addition of EtOAc (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0355] The first purification was performed using silica gel (60-120 mesh). The crude compound was adsorbed onto 60 g of silica gel and poured onto 500 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. The crude compound was adsorbed onto 18 g of neutral alumina and poured onto 130 g of neutral alumina in a column. The compound was eluted with 10% EtOAc / Hexane. Yield 1.2 g; Yield 43%; 1 Confirmed by 1 H NMR, HPLC and mass.
[0356] ATX-0086 / RL-48A: 1H-NMR(PPM,500MHz,CDCl3):δ=5.64(m,1),5.51(m,10,4.87(m,1),4.63(d,J=7.0,2),3.30~3.44(4),3.02(t ,J=7.0,2),2.52(t,J=7.0,2),2.26~2.36(4),2.27(s,6),2.09(m,2),1.82~1.96(4),1.46~1.54(4),1.21~1 .40(24), 0.84-0.91(9). Example 8: Synthesis of ATX-0087
[0357] FIG. 7 shows a synthetic route to ATX-0087 involving nine steps.
[0358] ATX-0087: Process 1 [ka]
[0359] A 2-liter two-neck round-bottom flask was charged with 20 g of octanoic acid dissolved in DCM (200 mL), then 1.5 equivalents of oxalyl chloride was added slowly at 0° C. with stirring under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 2 hours. In a separate 2-liter two-neck round-bottom flask, 2 equivalents of N,O-dimethylhydroxylamine hydrochloride in DCM (200 mL) was added with an addition funnel with stirring at 0° C. The resulting solution was concentrated under reduced pressure, and then the above acid chloride was added dropwise over 20 minutes with an addition funnel by dissolving it in DCM (150 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature for 3 hours under nitrogen atmosphere.
[0360] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexane). Yield 20 g; 84%.
[0361] ATX-0087: Process 2 [ka]
[0362] To a solution of hexylmagnesium bromide (1.5 equiv.) in THF (100 mL) placed in a 1 L, two-necked, round-bottom flask stirred at 0° C. under a nitrogen atmosphere was added a solution of 20 g of N-methoxy-N-methyloctanamide (1 equiv.) (dissolved in 200 mL of THF) and the resulting reaction mixture was stirred at room temperature for 4 h.
[0363] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (250 mL) followed by addition of EtOAc (350 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% EtOAc / hexanes). Yield 25 g; 65%.
[0364] ATX-0087: Process 3 [ka]
[0365] To a solution of 25 g of tridecan-7-one (1 eq.) in MeOH / THF was added 1.5 eq. of sodium borohydride at 0° C. and the resulting solution was stirred at room temperature for 1 h.
[0366] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (75 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 22 g; 90%.
[0367] ATX-0087: Process 4 [ka]
[0368] To a solution of 50 g of 4-aminobutanoic acid dissolved in 350 mL of THF was added 490 mL of aqueous 1N NaOH solution followed by 140 mL of Boc anhydride sequentially over 15 minutes using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0369] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (250 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 150 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 80 g; Yield 81%.
[0370] ATX-0087: Process 5 [ka]
[0371] To a solution of 17 g of 4-((tert-butoxycarbonyl)amino)butanoic acid in DCM (250 mL) and cooled to below 0° C., 1.3 equivalents of EDC.HCl, EtN 、and 4-dimethylaminopyridine (DMAP) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 1 equivalent of tridecan-7-ol was added at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0372] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5). The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then EtOAc (200 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude to next step. Yield 15 g (crude; required compound and alcohol).
[0373] ATX-0087: Process 6 [ka]
[0374] To a solution of 15.0 g of pentadecan-8-yl 4-((tert-butoxycarbonyl)amino)butanoate in 80 mL of DCM was added 10 equivalents of TFA at 0° C. and stirred at room temperature for 3 hours under nitrogen atmosphere.
[0375] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (300 mL) and then extracted with EtOAc (2 x 200 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield 7 g; 24% for two steps; confirmed by mass.
[0376] ATX-0087: Process 7 [ka]
[0377] To a solution of 4-bromobutyric acid dissolved in DCM (400 mL) and cooled below 0° C., 1.5 equivalents of EDC.HCl, 2 equivalents of Et3N, and DMAP were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 20 g of (Z)-non-2-en-1-ol was added by dissolving in 100 mL of DCM using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0378] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (300 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×150 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (200 mL) and then extracted with EtOAc (150 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexanes. The alcohol was recovered. Yield 19 g; 55%.
[0379] ATX-0087: Process 8 [ka]
[0380] To a solution of 4.0 g of tridecan-7-yl 4-aminobutanoate, 1 equivalent of (Z)-non-2-en-1-yl 4-bromobutanoate in 90 mL of ACN, 1.4 equivalents of potassium carbonate were added and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0381] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (20 mL) and the filtrate was concentrated under reduced pressure. The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 15% EtOAc / Hexane. The starting amine and bromo compounds were recovered. Yield 2.2 g; 30%; confirmed by mass.
[0382] ATX-0087: Process 9 [ka]
[0383] To a solution of 2.2 g of tridecan-7-yl (Z)-4-((4-(non-2-en-1-yloxy)-4-oxobutyl)amino)butanoate dissolved in 25 mL of dry DCM, 3 equivalents of triethylamine and triphosgene were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 hour under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0384] To 7 equivalents of sodium hydride dissolved in dry THF (100 mL) in a two-necked 100 mL round bottom flask stirred at 0° C. under nitrogen atmosphere, 3.5 equivalents of 2-(dimethylamino)propane-1-thiol hydrochloride was added and stirring continued for 5 minutes under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (100 mL) was slowly added via syringe over a period of about 10 minutes. The resulting solution was stirred overnight at 0° C. to room temperature under nitrogen atmosphere.
[0385] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (75 mL) followed by addition of EtOAc (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0386] The first purification was performed using silica gel (60-120 mesh). The crude compound was adsorbed onto 60 g of silica gel and poured onto 500 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. The crude compound was adsorbed onto 18 g of neutral alumina and poured onto 130 g of neutral alumina in a column. The compound was eluted with 10% EtOAc / Hexane. Yield 1.2 g; Yield 43%; 1 Confirmed by 1 H NMR, HPLC and mass.
[0387] ATX-0087 / RL-48C: 1 H-NMR(PPM,500MHz,CDCl3):δ=5.64(m,1),5.52(m,1),4.87(m,1),4.63(d,J=7.0,2),3.30~3.44(4),3.02(t,J=7.0,2), 2.52(t,J=7.0,2),2.26~2.36(4),2.27(s,6),2.09(m,2),1.83~1.96(4),1.46~1.54(4),1.21~1.40(32),0.85~0.90(9). Example 9: Synthesis of ATX-0088
[0388] FIG. 8 shows a synthetic route to ATX-0088, which is further described below.
[0389] ATX-0088: Process 1 [ka]
[0390] In a 500 mL two-neck round bottom flask under N2 atmosphere, 25 g of 8-bromooctanoic acid (1 eq.) dissolved in 200 mL of DCM was placed and then slowly added to oxalyl chloride (1.5 eq.) at 0° C. with stirring under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 2 h.
[0391] In a separate 1-liter two-neck round-bottom flask, 2 equivalents of N,O-dimethylhydroxylamine hydrochloride in 300 mL of DCM was added with 3 equivalents of trimethylamine and stirred at 0° C. To the resulting solution, after concentration under reduced pressure, the above acid chloride was added dropwise over 15 minutes using an addition funnel by dissolving it in 500 mL of DCM. The resulting reaction solution was stirred at room temperature for 3 hours under nitrogen atmosphere.
[0392] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (300 mL). The organic layer was separated and the aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure.
[0393] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 10% EtOAc / Hexanes). Yield: 21 g; Yield: 66%.
[0394] ATX-0088: Process 2 [ka]
[0395] To a solution of 1.3 equivalents of octylmagnesium bromide in THF (100 mL) stirred at 0° C. under nitrogen atmosphere, 20 g of N-methoxy-N-methyloctanamide in 100 mL of THF was added and the resulting reaction mixture was stirred at room temperature for 4 hours.
[0396] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure.
[0397] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 2% ethyl acetate / hexane). The yield was 17.4 g; 68%.
[0398] ATX-0088: Process 3 [ka]
[0399] To a solution of 17 g of hexadecan-7-one (1 eq.) in 135 mL of MeOH / THF was added 1.5 eq. of sodium borohydride at 0° C. and the resulting solution was stirred at room temperature for 1 h.
[0400] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (50 mL). Methanol was reduced under reduced pressure. The crude obtained was partitioned between EtOAc (200 mL) and water. The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 80 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 14.5 g; 85%.
[0401] ATX-0088: Process 4 [ka]
[0402] To a solution of 50 g of 4-aminobutanoic acid dissolved in 350 mL of THF was added 490 mL of aqueous 1N NaOH solution followed by 140 mL of Boc anhydride using a funnel at 0° C. The resulting solution was stirred at room temperature for 4 hours.
[0403] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (100 mL) followed by addition of EtOAc (200 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 80 g; Yield 81%.
[0404] ATX-0088: Process 5 [ka]
[0405] 1 equivalent of 4-((tert- To a solution of (butoxycarbonyl)amino)butanoic acid, 3 equivalents of EDC.HCl, Et3N (3 equivalents), and DMAP (0.1 equivalents) were added sequentially at 10 min intervals. To this resulting solution, the alcohol was added by dissolving in DCM using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0406] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mass was quenched with water (100 mL) and the organic layer was separated. The aqueous layer was washed with DCM (2×50 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution and EtOAc (100 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude. Yield 19 g (crude).
[0407] ATX-0088: Process 6 [ka]
[0408] To a solution of 19 g of hexadecan-7-yl 4-((tert-butoxycarbonyl)amino)butanoate (1 eq.) dissolved in 140 mL of DCM was added 10 eq. of TFA at 0° C. and stirred at room temperature under nitrogen atmosphere for 3 h.
[0409] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and EtOAc (100 mL) was added. The organic layer was separated and concentrated under reduced pressure.
[0410] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3) to recover the alcohol. Yield: 9.4 g; 50% for two steps; confirmed by mass.
[0411] ATX-0088: Process 7 [ka]
[0412] To a solution of 30 g of 4-bromobutyric acid (1 eq.) dissolved in DCM (500 mL) and cooled to 0° C., 1.5 eq. of EDC.HCl, 3 eq. of Et3N, and 0.1 eq. of DMAP were added sequentially at 10 min intervals. To this resulting solution, 0.7 eq. of (Z)-non-2-en-1-ol was added by dissolving in 100 mL of DCM using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0413] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.7). The reaction mass was quenched with water (100 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution and EtOAc (150 mL) was added. The organic layer was separated and concentrated under reduced pressure.
[0414] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 5% EtOAc / Hexanes). Yield: 27 g; Yield: 51%. 1 Confirmed by H NMR.
[0415] ATX-0088: Process 8 [ka]
[0416] To a solution of 6 g of hexadecan-8-yl 4-aminobutanoate (1 eq.), 1 eq. of 5(Z)-non-2-en-1-yl 4-bromobutanoate in ACN (70 mL) was added 1.2 eq. of potassium carbonate, and the resultant was refluxed at 90° C. for 3 h under a nitrogen atmosphere.
[0417] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5). The reaction mass was filtered and the filtrate was concentrated under reduced pressure.
[0418] The crude compound was subjected to column chromatography using (100-200 mesh silica gel; 15% EtOAc / Hexanes). Yield 4.5 g; Yield 44%; confirmed by mass.
[0419] ATX-0088: Process 9 [ka]
[0420] To a solution of 4.4 g of (Z)-non-2-en-1-yl 4-((4-oxo-4-(tetradecan-7-yloxy)butyl)amino)butanoate (1 eq.) dissolved in 30 mL of dry DCM, 0.83 mL of trimethylamine (3 eq.) and 418 mg of triphosgene (0.5 eq.) were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 h under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0421] To 192 mg of sodium hydride (10 eq.) dissolved in dry THF (25 mL) in a two-neck 100 mL round bottom flask was added 564 mg of 2-(dimethylamino)propane-1-thiol hydrochloride (5 eq.) at 0° C. and stirring was continued for 5 min under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (35 mL) was slowly added via syringe over a period of about 10 min. The resulting solution was stirred at room temperature under nitrogen atmosphere for 4 h.
[0422] The progress of the reaction was monitored by TLC (60% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (30 mL) followed by addition of EtOAc (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 50 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0423] The first purification was performed using silica gel (60-120 mesh). 5.0 g of crude compound was adsorbed onto 9 g of silica gel and poured onto 90 g of silica gel in a column. The compound was eluted with 35% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. 1.5 g of crude compound was adsorbed onto 4 g of neutral alumina and the resultant was poured onto 40 g of neutral alumina in a column. The compound was eluted with 10% EtOAc / Hexane. Yield 1.2 g; Yield 21%; 1 Confirmed by H NMR; HPLC; Mass.
[0424] ATX-0088 / RL-48D: 1 H-NMR (PPM, 500MHz, CDCl3): δ=5.64(m,1),5.51(m,1),4.87(m,1),4.63(d,J=7.0,2),3.30~3.44(4),2.90(t,J=7.0,2),2. 46~2.55(6),2.26~2.37(4),2.09(m,2),1.71~1.80(4),1.46~1.55(4),1.21~1.41(32),1.01(t,J=7.0,6),00.85~0.91(9). Example 10: Synthesis of ATX-0083
[0425] FIG. 9 shows a synthetic route to ATX-0083, which is further described below.
[0426] ATX-0083: Process 1 [ka]
[0427] In a 500 mL single-neck round-bottom flask, 50 g of octanoic acid (1 eq.) dissolved in DCM (200 mL) was placed and then 44.6 mL of oxalyl chloride (1.5 eq.) was added slowly via an addition funnel at 0° C. with stirring under a nitrogen atmosphere, followed by 1 mL of DMF (catalyst). The resulting reaction mixture was stirred at room temperature for 2 hours.
[0428] In a separate 2-liter two-neck round-bottom flask, 67.4 g of N,O-dimethylhydroxylamine hydrochloride (2 eq.) in DCM (300 mL) was added with an addition funnel of 144 mL of triethylamine (3 eq.) stirred at 0° C. After concentrating under reduced pressure, the above acid chloride was added dropwise over 20 minutes with an addition funnel by dissolving it in DCM (350 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature under nitrogen atmosphere for 3 hours.
[0429] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was diluted with water (300 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0430] The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 10% EtOAc / Hexanes. Yield: 55.0 g; Yield: 84%
[0431] ATX-0083: Process 2 [ka]
[0432] To a solution of 55 g of heptylmagnesium bromide (1 eq.) in ether in a 2 L two-necked round-bottom flask stirred at 0° C. under nitrogen, a solution of 89.6 g of N-methoxy-N-methyloctanamide (1.5 eq.) dissolved in 400 mL of dry ether was added and the resulting reaction solution was stirred at room temperature for 4 hours.
[0433] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7; PMA char). The reaction mass was quenched with saturated NH4Cl solution (250 mL). The organic layer was separated and the aqueous layer was washed with ether (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0434] The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 2% EtOAc / Hexanes. Yield: 50.0 g; Yield: 75%.
[0435] ATX-0083: Process 3 [ka]
[0436] To a solution of 50 g of pentadecan-8-one (1 eq.) in 290 mL of MeOH / THF was added 12.5 g of sodium borohydride (1.5 eq.) at 0° C. and the resulting solution was stirred at room temperature for 2 h.
[0437] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (80 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (250 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 80 mL). The combined organic layers were dried over anhydrous Na2SO4, concentrated under reduced pressure and dried under vacuum to give a white solid. Yield 46.0 g; 90%.
[0438] ATX-0083: Process 4 [ka]
[0439] To a solution of 50 g of 4-aminobutanoic acid (1 eq.) in THF was added 490 mL of 1 N aqueous NaOH solution (1 eq.) followed by 140 mL of Boc anhydride (1.3 eq.) sequentially over 15 min using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 h.
[0440] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (350 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 150 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a gummy liquid. Yield 77.0 g; Yield 78%.
[0441] ATX-0083: Process 5 [ka]
[0442] The synthesis was carried out in four batches. In each batch, 32.3 g of EDC.HCl (1.5 eq.), 47 mL of Et3N (3 eq.), and 1.3 g of DMAP (0.1 eq.) were added sequentially at 10 min intervals to a solution of 23 g of 4-((tert-butoxycarbonyl)amino)butanoic acid (1 eq.) in DCM (400 mL) cooled below 0° C. under nitrogen atmosphere. To the resulting solution, 20 g of pentadecan-8-ol (0.77 eq.) was added by dissolving in DCM (200 mL) using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0443] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.4). The reaction mass was quenched with water (250 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. This crude obtained was washed with saturated NaHCO3 solution (150 mL) and EtOAc (250 mL) was added. The organic layer was separated, dried over anhydrous Na2SO4, concentrated under reduced pressure and then taken crude to next step. Yield 105 g (crude; required compound and alcohol).
[0444] ATX-0083: Process 6 [ka]
[0445] To a solution of 105 g of pentadecan-8-yl 4-((tert-butoxycarbonyl)amino)butanoate (1 eq.) in 450 mL of DCM was added 194 mL of TFA (10 eq.) at 0° C. and stirred at room temperature for 3 h under a nitrogen atmosphere.
[0446] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3).
[0447] The reaction mass was concentrated under reduced pressure. The crude obtained was stirred with saturated NaHCO3 solution (200 mL) for 10 min and then with EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0448] The crude compound was subjected to column chromatography (silica gel 60-120 mesh) using 4% MeOH / CHCl3 and 1 mL of triethylamine. Production: 60.0 g over two steps; yield: 54%.
[0449] ATX-0083: Process 7 [ka]
[0450] The reaction was carried out in two portions, in which 29.3 g of EDC.HCl (1.5 eq.), 42.8 mL of Et3N (3 eq.), and 1.2 g of DMAP (0.1 eq.) were added sequentially at 10 min intervals under nitrogen atmosphere to a solution of 20 g of 6-bromohexanoic acid (1 eq.) dissolved in DCM (300 mL) and cooled below 0° C. To the resulting solution was added 14.5 g of (Z)-non-2-en-1-ol (1 eq.) (by dissolving in 100 mL of DCM) using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0451] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (200 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then extracted with EtOAc (2×150 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0452] The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 4% EtOAc / Hexanes. The alcohol reactant was collected. Yield 36.0 g; 55%.
[0453] ATX-0083: Process 8 [ka]
[0454] The reaction was carried out in six batches, in each of which, to a solution of 10 g of pentadecan-8-yl 4-aminobutanoate (Int6, 1 eq.), 10.1 g of (Z)-non-2-en-1-yl 6-bromohexanoate (Int7, 1 eq.) in 120 mL of ACN, 6.1 g of anhydrous potassium carbonate (1.4 eq.) was added, and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0455] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (2 x 20 mL) and the filtrate was concentrated under reduced pressure.
[0456] The crude compound was subjected to column chromatography (silica gel 100-200 mesh) using 20-80% EtOAc / Hexane. The starting material was recovered. Yield 36.9 g; Yield 35%.
[0457] ATX-0083: Process 9 [ka]
[0458] The reaction was carried out in three portions. In each, to a solution of 10 g of (Z)-non-2-en-1-yl 6-((4-oxo-4-(pentadecan-8-yloxy)butyl)amino)hexanoate (1 eq.) dissolved in 100 mL of dry DCM, 7.5 mL of triethylamine (3 eq.) and 2.68 g of triphosgene (0.5 eq.) were added at 0° C. in 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 h under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0459] To a suspension of 3 g of sodium hydride (7 eq.) in dry THF (100 mL) in a two-necked 500 mL RB flask stirred at 0° C. under nitrogen atmosphere, 8.9 g of 2-(dimethylamino)ethane-1-thiol hydrochloride (3.5 eq.) was added and stirring was continued for 5 min under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in dry THF (200 mL) was slowly added via syringe over a period of about 10 min. The resulting solution was stirred at room temperature under nitrogen atmosphere overnight.
[0460] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (100 mL) followed by addition of EtOAc (350 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2×80 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0461] The first purification was performed using neutral alumina. The crude compound dissolved in hexane was loaded on top of neutral alumina (700 g loaded in the column). The compound was eluted with 8-10% EtOAc / Hexane. The second purification was performed using silica gel (100-200 mesh). The compound dissolved in hexane was loaded on top of silica gel (500 g loaded in the column). The compound was eluted with 20-25% EtOAc / Hexane. The final compound (dissolved in hexane) was charcoal treated (200 mg / g), filtered through a bed of celite (after stirring for 20 min) and then passed through a syringe-end membrane filter (PTFE; 0.2 micron, 25 mm diameter). The resulting filtrate was concentrated under reduced pressure. Yield 15.5 g; yield 41 %.
[0462] ATX-0083 / RL-47B: 1 H-NMR (PPM, 500MHz, CDCl3): δ=5.64(m,1),5.52(m,1),4.87(m,1),4.62(d,J=7.0,2),3.24~3.42(4),3.02(t,J=7 .0,2),2.53(t,J=7.0,2),2.26~2.34(4),2.26(s,6),2.10(m,2),1.45~1.70(6),1.20~1.41(34),0.84~0.92(9). Example 11: Synthesis of ATX-0084
[0463] FIG. 10 shows a synthetic route to ATX-0084, which is further described below.
[0464] ATX-0084: Process 1 [ka]
[0465] In a 500 mL single-neck round-bottom flask, 30 g of heptanoic acid (1 eq.) dissolved in DCM (200 mL) was placed, and then 26.7 g of oxalyl chloride (1.5 eq.) was slowly added at 0° C. with stirring under nitrogen atmosphere, followed by 1 mL of DMF (catalyst). The resulting reaction mixture was stirred at room temperature for 2 hours.
[0466] In a separate 1 L two-neck round bottom flask, 40.5 g of N,O-dimethylhydroxylamine hydrochloride (2 eq.) in DCM (250 mL) was added with an addition funnel of 86.6 mL of trimethylamine (3 eq.) stirred at 0° C. After concentration under reduced pressure, the above acid chloride was added dropwise over 20 min with an addition funnel by dissolving it in DCM (100 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature under nitrogen atmosphere for 3 h.
[0467] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure.
[0468] The crude compound was subjected to column chromatography (60-120 silica gel) using 10% EtOAc / Hexanes. Yield: 38.0 g; 84%.
[0469] ATX-0084: Process 2 [ka]
[0470] To a solution of 8 g of hexylmagnesium bromide (1 eq.) in 250 mL of dry ether placed in a 1-L two-neck round-bottom flask and stirred at 0° C. under nitrogen atmosphere, 2.3 g of N-methoxy-N-methylheptanamide (0.5 eq.) dissolved in 250 mL of ether was added and the resulting reaction mixture was stirred at room temperature for 4 h.
[0471] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with saturated NH4Cl solution (200 mL). The organic layer was separated and the aqueous layer was washed with ether (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0472] The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 2% EtOAc / Hexanes. Yield: 30.8 g; Yield: 71%.
[0473] ATX-0084: Process 3 [ka]
[0474] To a solution of 30 g of tridecan-7-one (1 eq.) in 200 mL of MeOH / THF was added 8.5 g of sodium borohydride (0.5 eq.) at 0° C. and the resulting solution was stirred at room temperature for 2 h.
[0475] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mass was quenched with saturated NH4Cl solution (80 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (200 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 70 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 27.2 g; 90%.
[0476] ATX-0084: Process 4 [ka]
[0477] To a solution of 5 g of 6-aminohexanoic acid (1 equiv.) in 120 mL of THF was added 125 mL of 1 N aqueous NaOH solution followed by 34 mL of Boc anhydride (1.3 equiv.) over a period of 15 min using an addition funnel at 0° C. The resulting solution was stirred at room temperature for 4 h.
[0478] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was quenched with 5% HCl (100 mL) followed by addition of EtOAc (150 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 22.4 g; 85%.
[0479] ATX-0084: Process 5 [ka]
[0480] To a solution of 10 g of 6-((tert-butoxycarbonyl)amino)hexanoic acid (1 eq.) dissolved in DCM (200 mL) and cooled to below 0° C., 10.7 g of EDC.HCl (1.3 eq.), 18 mL of Et3N (3 eq.), and 525 mg of DMAP (0.1 eq.) were added sequentially at 10 min intervals under a nitrogen atmosphere. Using this, 6 g of tridecan-7-ol (Int3, 0.7 eq.) was added at the same temperature by dissolving in DCM (50 mL) and stirred at room temperature for 24 h under nitrogen atmosphere.
[0481] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.4). The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2 x 75 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then extracted with EtOAc (2 x 100 mL) and added. The organic layer was separated and concentrated under reduced pressure and taken forward crude. Yield 8.5 g (crude; required compound and alcohol).
[0482] ATX-0084: Process 6 [ka]
[0483] To a solution of 10 g of tridecan-7-yl 6-((tert-butoxycarbonyl)amino)hexanoate (1 eq.) dissolved in 65 mL of DCM was added 18.5 mL of TFA (10 eq.) at 0° C. and stirred at room temperature for 3 h under nitrogen atmosphere.
[0484] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then extracted with EtOAc (3 x 100 mL). The organic layer was separated and concentrated under reduced pressure.
[0485] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol starting material. Amount 4.5 g for two steps; yield 33%.
[0486] ATX-0084: Process 7 [ka]
[0487] To a solution of 20 g of 6-bromohexanoic acid (1 equiv.) in DCM (300 mL) and cooled below 0° C., 29.3 g of EDC.HCl (1.5 equiv.), 42.8 mL of Et3N (3 equiv.), and 1.2 g of DMAP (0.1 equiv.) were added sequentially at 10 min intervals under nitrogen atmosphere. To the resulting solution, 14.5 g of (Z)-non-2-en-1-ol (1 equiv.) dissolved in 100 mL of DCM was added using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0488] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7). The reaction mass was quenched with water (200 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then extracted with EtOAc (2×150 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0489] The crude compound was purified by column chromatography (60 -120 mesh silica gel). The alcohol starting material was recovered. Yield: 18.0 g; 55%.
[0490] ATX-0084: Process 8 [ka]
[0491] To a solution of 4.5 g of tridecan-7-yl 6-aminohexanoate (Int6, 1 eq.), 4.5 g of (Z)-non-2-en-1-yl 6-bromohexanoate (Int7, 1 eq.) in 90 mL of ACN, 2.7 g of potassium carbonate (1.4 eq.) was added and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0492] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5). The reaction mass was filtered, washed with ACN (2 x 20 mL) and the filtrate was concentrated under reduced pressure.
[0493] The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 20% EtOAc / Hexanes. The starting material was recovered. Yield 3.0 g; 37%.
[0494] ATX-0084: Process 9 [ka]
[0495] To a solution of 2.5 g of (Z)-non-2-en-1-yl 6-((6-oxo-6-(tridecan-7-yloxy)hexyl)amino)hexanoate (1 eq.) dissolved in 30 mL of dry DCM, 1.8 mL of triethylamine (3 eq.) and 672 mg of triphosgene (0.5 eq.) were added at 0° C. at 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature for 1 h under nitrogen atmosphere. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0496] To a suspension of 761 mg of sodium hydride in dry THF (50 mL) in a two-necked 250 mL round bottom flask stirred at 0° C. under nitrogen atmosphere, 2.2 g of 2-(dimethylamino)ethane-1-thiol hydrochloride (3.5 eq.) was added and stirring was continued for 5 min under nitrogen atmosphere. To this resulting solution, the above carbamoyl chloride dissolved in THF (60 mL) was slowly added via syringe over a period of about 10 min. The resulting solution was stirred at room temperature under nitrogen atmosphere overnight.
[0497] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5; PMA char). The reaction mass was quenched with saturated NH4Cl solution (60 mL) followed by addition of EtOAc (130 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography.
[0498] The first purification was performed using silica gel (100-200 mesh). 4.6 g of crude compound was adsorbed onto 10.0 g of silica gel and poured onto 90.0 g of silica gel in a column. The compound was eluted with 50% EtOAc / Hexane. The second purification was performed using neutral alumina with HPLC grade solvent. 2.0 g of crude compound was adsorbed onto 6.0 g of neutral alumina and the resultant was poured onto 40.0 g of neutral alumina in a column. The compound was eluted with 20% EtOAc / Hexane. Yield 1.2 g; yield 38% (300 mg mixture).
[0499] ATX-0084 / RL-47C: 1 H-NMR (PPM, 500MHz, CDCl3): δ=5.64(m,1),5.52(m,1),4.86(m,1),4.62(d,J=7.0,2),3.22~3.35(4),3.01(t,J=7. 0,2),2.53(t,J=7.0,2),2.25~2.34(4),2.27(s,6),2.10(m,2),1.45~1-73(10),1.20~1.40(30),00.84~0.91(9). Example 12: Synthesis of ATX-0061
[0500] FIG. 11 shows a synthetic route to ATX-0061, which is further described below.
[0501] ATX-0061: Process 1 [ka]
[0502] 12 g of glycine ester (1 eq.) was dissolved in THF (100 mL) and cooled to below 0° C. To this solution were added 24.2 mL of triethylamine (1.5 eq.) and 38.11 g of Boc anhydride (1.5 eq.) sequentially via addition funnel.
[0503] The progress of the reaction was monitored by TLC using 50% EtOAc / Hexanes; Rf: 0.4.
[0504] The reaction mass was quenched with water and EtOAc (100 mL) was added after 16 h. The organic layer was separated and the aqueous layer was washed with EtOAc (2×40 mL) and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure.
[0505] The crude product was loaded onto 60-120 silica gel (25% EtOAc / Hexanes). Amount 20.8; Yield 88%.
[0506] ATX-0061: Process 2 [ka]
[0507] To a solution of 18.9 g of N-Boc glycine ester (1 eq.) dissolved in THF (130 mL) was added an aqueous solution of 5.85 g of LiOH (1.5 eq.) and the resulting solution was stirred at room temperature for 4 h.
[0508] The reaction was monitored by TLC (60% EtOAc / Hexanes; Rf: 0.3) and no SM was present.
[0509] The reaction mass was concentrated and the crude mass was quenched with 5% HCl (pH 3), then extracted with EtOAc (4×80 mL), dried over sodium sulfate and concentrated under reduced pressure to give compound: Yield 15 g; Yield 92%; confirmed by mass.
[0510] ATX-0061: Process 3 [ka]
[0511] To a solution of 5 g of N-Boc-glycine ester (Int1, 1 eq.) dissolved in DCM (30 mL) and cooled below 0° C., 4.5 mL of Et3N (1.2 eq.) and 6.44 g of EDC.HCl (1.2 eq.) were added. To this reaction solution, 5.12 g of heptaden-9-ol (0.7 eq.) in 20 mL of DCM was added and stirred at room temperature overnight.
[0512] No starting material was present as determined by TLC (10% EtOAc / Hexanes; Rf: 0.6). The reaction mass was diluted with saturated NaHCO3 solution, the organic layer was separated, and the aqueous layer was washed with DCM (2 x 30 mL), dried over sodium sulfate, and concentrated under reduced pressure. The crude (6.8 g; mixture of product and alcohol) was carried forward to the next step.
[0513] ATX-0061: Process 4 [ka]
[0514] 4 g of heptadecan-9-yl(tert-butoxycarbonyl)glycinate (Int2, 1 eq.) was dissolved in DCM (40 mL), cooled to 0° C., 7.4 mL of TFA (10 eq.) was added and stirred at room temperature for 1 h.
[0515] The reaction was complete by TLC in 2 hours (10% EtOAc / Hexanes; Rf: 0.5).
[0516] The reaction mass was concentrated under reduced pressure and the residual mass was washed with saturated sodium bicarbonate solution (30 mL), Extraction with EtOAc (3×30 mL) and the organic layer was dried over sodium sulfate and concentrated under reduced pressure to give Int3.
[0517] The crude product was subjected to column chromatography (silica, 60-120) using 1-3% MeOH / CHCl3 and 2 mL of Et3N. Yield 1 g; 1 Confirmed by H-NMR and mass.
[0518] ATX-0061: Process 5 [ka]
[0519] To a solution of 4 g bromoacetic acid (1 equiv.) dissolved in DCM (35 mL) and cooled below 0° C. was added 4.7 mL EtN (1.2 equiv.) and 354 mg DMAP (0.1 equiv.) followed by 13.23 g HATU (1.2 equiv.) To this reaction solution was added 2.88 g (Z)-non-2-en-1-ol (0.7 equiv.) in 20 mL DCM and stirred at room temperature overnight.
[0520] The reaction was monitored by TLC (10% EtOAc / Hexanes; Rf: 0.7).
[0521] The reaction mass was diluted with saturated NaHCO3 solution (80 mL), the organic layer was separated, the aqueous layer was washed with DCM (40 mL), dried over sodium sulfate and concentrated under reduced pressure. The residual mass was purified by silica gel (60-120) column chromatography (1.5% EtOAc / Hexane). Yield 4 g; Yield 52%.
[0522] ATX-0061: Process 6 [ka]
[0523] 1 g of heptadecane-9-yl glycinate (Int3, 1 eq.) was dissolved in THF (25 mL), 0.5 mL of TEA (1.3 eq.) and 1.08 g of (Z)-non-2-en-1-yl 2-bromoacetate derivative (Int4, 1.3 eq.) were added and stirred at room temperature overnight.
[0524] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.4). The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (20 mL×2), and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure.
[0525] The residual mass was purified by column (silica gel; 100-200) chromatography (2% EtOAc / hexane). Product amount 700 mg; yield 47%; confirmed by mass.
[0526] ATX-0061: Process 7 [ka]
[0527] To a solution of 700 mg of heptadecan-9-yl (Z)-(2-(non-2-en-1-yloxy)-2-oxoethyl)glycinate) (1 eq.) dissolved in 15 mL of DCM and cooled to below 5° C., 0.4 mL of EtN (3 eq.) was added followed by 209 mg of triphosgene (0.5 eq.) in small portions over 10 min.
[0528] The progress of the reaction mixture monitored by TLC was complete in 0.5 h and the reaction mass was concentrated under reduced pressure.
[0529] To a solution of 423 mg of N,N-dimethylethanethiol hydrochloride (3 eq.) in dry THF (10 mL) and DMF (3 mL) stirred under nitrogen atmosphere at 0° C., 144 mg of sodium hydride (6 eq.) was added. After 10 minutes, the above solution was added to the reaction mass by dissolving it in THF (15 mL). The resulting solution was stirred at room temperature for 1 hour.
[0530] The reaction was complete after 1 h as confirmed by TLC (10% MeOH / CHCl3; Rf: 0.5).
[0531] The reaction mass was quenched with saturated NH4Cl solution (20 mL) and water (20 mL) and EtOAc (30 mL) were added. The aqueous layer was washed with EtOAc (2×20 mL) and the combined organic layers were washed with brine solution (20 mL). The organic layers were dried over Na2SO4 and concentrated under reduced pressure.
[0532] The crude material was subjected to column chromatography using silica gel (100-200) with 15% EtOAc / Hexane, followed by neutral alumina with 15% EtOAc / Hexane to give the pure compound. Yield: 520 mg; Yield: 58%. 1 Confirmed by H-NMR, HPLC, and mass.
[0533] ATX-0061 / RL-42D: 1 H-NMR(PPM,400MHz,CDCl3):δ=5.67(m,1),5.51(m,1),4.92(m,1),4.70(m,2),4.16~4.27(4), 3.07(m,2),2.53(m,2),2.27(s,6),2.10(m,2),1-47~1.57(4),1.19~1.40(32),0.83~0.92(9). Example 13: Synthesis of ATX-0063
[0534] FIG. 12 shows a synthetic route to ATX-0063, which is further described below.
[0535] ATX-0063: Process 1 [ka]
[0536] 12 g of glycine ester (1 eq.) was dissolved in THF (100 mL) and cooled to below 0° C. To this solution were added 24.2 mL of triethylamine (1.5 eq.) and 38.11 g of Boc anhydride (1.5 eq.) sequentially via addition funnel.
[0537] The progress of the reaction was monitored by TLC using 50% EtOAc / Hexanes; Rf: 0.4.
[0538] The reaction mass was quenched with water and EtOAc (100 mL) was added after 16 h. The organic layer was separated and the aqueous layer was washed with EtOAc (2×40 mL) and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure.
[0539] The crude product was loaded onto 60-120 silica gel (25% EtOAc / Hexanes): Yield 20.8; Yield 88%.
[0540] ATX-0063: Process 2 [ka]
[0541] To a solution of 18.9 g of N-Boc glycine ester (1 eq.) dissolved in THF (130 mL) was added an aqueous solution of 5.85 g of LiOH (1.5 eq.) and the resulting solution was stirred at room temperature for 4 h.
[0542] The reaction was monitored by TLC (60% EtOAc / Hexanes; Rf: 0.3) and no starting material was present in the reaction product.
[0543] The reaction mass was concentrated and the crude mass was quenched with 5% HCl (pH 3), then extracted with EtOAc (4×80 mL), dried over sodium sulfate and concentrated under reduced pressure to give compound: Yield 15 g; Yield 92%; confirmed by mass.
[0544] ATX-0063: Process 3 [ka]
[0545] To a solution of 5 g of N-Boc-glycine ester (Int1, 1 eq.) dissolved in DCM (50 mL) and cooled below 0° C., 4.5 mL of Et3N (1.2 eq.) and 6.4 g of EDC.HCl (1.2 eq.) were added. To this reaction solution, 3.4 g of undecan-6-ol (0.7 eq.) in 20 mL of DCM was added and stirred at room temperature overnight.
[0546] No starting material was present by TLC (15% EtOAc / Hex Rf: 0.6). The reaction mass was diluted with saturated NaHCO3 solution (20 mL), the organic layer was separated and the aqueous layer was washed with DCM (2 x 40 mL), dried over sodium sulfate and concentrated under reduced pressure. After column filtration, the crude (5.5 g; mixture of product and alcohol) was carried forward to next step.
[0547] ATX-0063: Process 4 [ka]
[0548] 3.3 g of crude undecan-6-yl(tert-butoxycarbonyl)glycinate (Int2, 1 eq.) was dissolved in DCM (20 mL), cooled to 0° C., 7.6 mL of TFA (10 eq.) was added and stirred at room temperature for 1 h.
[0549] Completion of the reaction was confirmed by TLC in 2 h (10% MeOH / DCM; Rf: 0.5). The reaction mass was concentrated under reduced pressure, the residual mass was washed with saturated sodium bicarbonate solution (50 mL), extracted with EtOAc (3×25 mL), the organic layer was dried over sodium sulfate and concentrated under reduced pressure to give Int3.
[0550] The crude product was subjected to column chromatography (silica, 60-120) using 1-3% MeOH / CHCl3 and 2 mL of Et3N. Yield: 1.2 g; Yield: 40%. 1 Confirmed by H-NMR and mass.
[0551] ATX-0063: Process 5 [ka]
[0552] To a solution of 4 g bromoacetic acid (1 equiv.) dissolved in DCM (35 mL) and cooled below 0° C. was added 4.7 mL EtN (1.2 equiv.), followed by 13.23 g HATU (1.2 equiv.) and 354 mg DMAP (0.1 equiv.) To this reaction solution was added 2.88 g (Z)-non-2-en-1-ol (0.7 equiv.) in 20 mL DCM and stirred at room temperature overnight.
[0553] The reaction was monitored by TLC (10% EtOAc / Hexanes; Rf: 0.7).
[0554] The reaction mass was diluted with saturated NaHCO3 solution (80 mL), the organic layer was separated, the aqueous layer was washed with DCM (40 mL), dried over sodium sulfate and concentrated under reduced pressure. The residual mass was purified by silica gel (60-120) column chromatography (1.5% EtOAc / Hexane). Yield 4 g; Yield 52%.
[0555] ATX-0063: Process 6 [ka]
[0556] 1.2 g of undecane-6-yl glycinate (Int3, 1 eq.) was dissolved in 25 mL of THF, 0.9 mL of TEA (1.3 eq.) and 1.37 g of (Z)-non-2-en-1-yl 2-bromoacetate (Int4, 1 eq.) were added and stirred at room temperature overnight.
[0557] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (20 mL×2), and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure.
[0558] The residual mass was purified by column (silica gel; 100-200) chromatography (3% EtOAc / hexane). Product amount: 800 mg; yield: 37%; confirmed by mass.
[0559] ATX-0063: Process 7 [ka]
[0560] To a solution of 800 mg of (Z)-non-2-en-1-yl(2-oxo-2-(undecane-6-yloxy)ethyl)glycinate) (1 eq.) dissolved in DCM and cooled to below 5° C., 0.4 mL of EtN (3 eq.) was added in portions over 10 min, followed by 209 mg of triphosgene (0.5 eq.).
[0561] The progress of the reaction mixture monitored by TLC was complete in 1 hour and the reaction mass was concentrated under reduced pressure.
[0562] To a solution of 423 mg of N,N-dimethylethanethiol hydrochloride (3 eq.) in dry THF and DMF (10 mL and 5 mL, respectively) stirred under nitrogen atmosphere at 0° C., 144 mg of sodium hydride (6 eq.) was added. After 10 minutes, the above solution was added by dissolving it in THF to the reaction mass. The resulting solution was stirred at room temperature for 1 hour.
[0563] Completion of the reaction was confirmed by TLC after 1 h (70% EtOAc / Hexane; Rf: 0.4). The reaction mass was quenched with saturated NH4Cl solution (25 mL) and water (20 mL) and EtOAc (20 mL) were added. The aqueous layer was washed with EtOAc (2×20 mL) and the combined organic layers were washed with brine solution (20 mL). The organic layers were dried over Na2SO4 and concentrated under reduced pressure.
[0564] The crude material was purified by column chromatography using silica gel (100-200) with 20% EtOAc / hexane, followed by neutral alumina with 5% EtOAc / hexane. The pure compound was obtained. Yield: 48%. 1 Confirmed by H-NMR, HPLC, and mass.
[0565] ATX-0063 / RL-42A: 1 H-NMR(PPM,400MHz,CDCl3):δ=5.67(m,1),5.52(m,1),4.92(m,1),4.70(m,2),4.15~4.27(4), 3.06(m,2),2.53(m,2),2.27(s,6),2.09(m,2),1.47~1.57(4),1.20~1.41(20),0.82~0.92(9). Example 14: Synthesis of ATX-0064
[0566] FIG. 13 shows a synthetic route to ATX-0064, which is further described below.
[0567] ATX-0064: Process 1 [ka]
[0568] 12 g of ethyl glycinate (1 eq.) was dissolved in THF (100 mL) and cooled to below 0° C. To this resulting solution was added 24.2 mL of triethylamine (1.5 eq.) and 38.11 g of Boc anhydride (1.5 eq.) sequentially via addition funnel.
[0569] The progress of the reaction was monitored by TLC using 50% EtOAc / Hexanes; Rf: 0.4.
[0570] The reaction mass was quenched with water and EtOAc (100 mL) was added after 16 h. The organic layer was separated and the aqueous layer was washed with EtOAc (2×40 mL) and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure.
[0571] The crude product was loaded onto 60-120 silica gel (25% EtOAc / Hexanes): Yield 20.8; Yield 88%.
[0572] ATX-0064: Process 2 [ka]
[0573] To a solution of 18.9 g of N-Boc glycine ester (1 eq.) dissolved in THF (130 mL) was added an aqueous solution of 5.85 g of LiOH (1.5 eq.) and the resulting solution was stirred at room temperature for 4 h.
[0574] The reaction was monitored by TLC (60% EtOAc / Hexanes; Rf: 0.3) and no starting material was present in the reaction product.
[0575] The reaction mass was concentrated and the crude mass was quenched with 5% HCl (pH 3), then extracted with EtOAc (4×80 mL), dried over sodium sulfate and concentrated under reduced pressure to give compound: Yield 15 g; Yield 92%; confirmed by mass.
[0576] ATX-0064: Process 3 [ka]
[0577] To a solution of 5 g of N-Boc-glycine ester (Int1, 1 eq.) dissolved in DCM (50 mL) and cooled below 0° C., 4.5 mL of Et3N (1.2 eq.) and 6.4 g of EDC.HCl (1.2 eq.) were added. To this reaction solution, 4.84 g of hexadecan-10-ol (0.7 eq.) in 15 mL of DCM was added and stirred at room temperature overnight.
[0578] No starting material was present as determined by TLC (15% EtOAc / Hexanes; Rf: 0.6). The reaction mass was diluted with saturated NaHCO3 solution, the organic layer was separated and the aqueous layer was washed with DCM (2 x 30 mL), dried over sodium sulfate and concentrated under reduced pressure.
[0579] After column filtration, the crude (5.5 g; mixture of product and alcohol) was carried on to the next step.
[0580] ATX-0064: Process 4 [ka]
[0581] 3.85 g of crude heptadecan-9-yl(tert-butoxycarbonyl)glycinate (Int2, 1 eq.) was dissolved in 30 mL of DCM, cooled to 0° C., 7.4 mL of TFA (10 eq.) was added and stirred at room temperature for 1 h.
[0582] The reaction was complete by TLC in 2 hours (10% MeOH / DCM; Rf: 0.5).
[0583] The reaction mass was concentrated under reduced pressure and the residual mass was washed with saturated sodium bicarbonate solution (30 mL) and extracted with EtOAc (3×30 mL), the organic layer was dried over sodium sulfate and concentrated under reduced pressure to give Int3.
[0584] The crude product was subjected to column chromatography (silica, 60-120) using 1-3% MeOH / CHCl3 and 2 mL of Et3N. Yield 2.2 g; 1 Confirmed by H-NMR and mass.
[0585] ATX-0064: Process 5 [ka]
[0586] To a solution of 4 g of bromoacetic acid (1 equiv.) dissolved in DCM (35 mL) and cooled to below 0° C., 4.7 mL of EtN (1.2 equiv.) was added, followed by 13.23 g of HATU (1.2 equiv.) and 354 mg of DMAP (0.1 equiv.). 2.88 g of (Z)-non-2-en-1-ol (0.7 eq.) in DCM was added and stirred at room temperature overnight.
[0587] The reaction was monitored by TLC (10% EtOAc / Hexanes; Rf: 0.7).
[0588] The reaction mass was diluted with saturated NaHCO3 solution (80 mL), the organic layer was separated and the aqueous layer was washed with DCM (40 mL), dried over sodium sulfate and concentrated under reduced pressure.
[0589] The residual mass was purified by silica gel (60-120) column chromatography (1.5% EtOAc / Hexane). Yield: 4 g; Yield: 52%.
[0590] ATX-0064: Process 6 [ka]
[0591] 2.1 g of hexadecan-8-yl glycinate (Int3, 1 eq.) was dissolved in 50 mL of THF, 1.2 mL of TEA (1.3 eq.) and 2.39 g of (Z)-non-2-en-1-yl 2-bromoacetate (Int4, 1.3 eq.) were added and stirred at room temperature overnight.
[0592] The progress of the reaction was monitored by TLC (10% EtOAc / Hexane; Rf: 0.5). The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2×30 mL), and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure.
[0593] The residual mass was purified by column (silica gel; 100-200) chromatography (3% EtOAc / hexane). Product weight: 2.2 g; yield: 65%; confirmed by mass.
[0594] ATX-0064: Process 7 [ka]
[0595] To a solution of 2.2 g heptadecan-9-yl (Z)-(2-(non-2-en-1-yloxy)-2-oxoethyl)glycinate) (1 eq.) dissolved in 15 mL DCM and cooled to below 5° C., 1.6 mL EtN (3 eq.) was added in portions over 10 min, followed by 678 mg triphosgene (0.5 eq.).
[0596] The progress of the reaction mixture monitored by TLC was complete in 1 hour and the reaction mass was concentrated under reduced pressure.
[0597] To a solution of 3.94 g of N,N-dimethylethanethiol hydrochloride (7 eq.) in dry THF and DMF (35 mL and 15 mL, respectively) stirred under nitrogen atmosphere at 0° C., 672 mg of sodium hydride (7 eq.) was added. After 10 minutes, the above solution was added by dissolving it in THF to the reaction mass. The resulting solution was stirred at room temperature for 1 hour.
[0598] Completion of the reaction was confirmed by TLC after 1 h (70% EtOAc / Hexane; Rf: 0.4). The reaction mass was quenched with saturated NH4Cl solution (25 mL) and water (20 mL) and EtOAc (20 mL) were added. The aqueous layer was washed with EtOAc (20 mL x 2) and the combined organic layer was washed with brine solution (20 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure.
[0599] The crude material was subjected to column chromatography using silica gel (100-200) with 25% EtOAc / Hexane, followed by neutral alumina with 15-20% EtOAc / Hexane to give the pure compound. Yield: 1.0 mg; Yield: 40%. 1 Confirmed by H-NMR, HPLC, and mass.
[0600] ATX-0064 / RL-42C: 1H-NMR(PPM,400MHz,CDCl3):δ=5.67(m,1),5.50(m,1),4.92(m,1),4.70(t,J=7.0,2) ,3.06(,m,2),2.53(m,2),2.27(s,6),1.47~1.57(4),1.17~1.40(30),0.82~0.93(9). Example 15: Synthesis of ATX-0081
[0601] FIG. 14 shows a synthetic route to ATX-0081, which is further described below.
[0602] ATX-0081: Process 1 [ka]
[0603] To a solution of heptylmagnesium bromide (1.5 equiv.) in 370 mL of dry THF (generated in situ) cooled to −15° C. under a nitrogen atmosphere, ethyl formate (0.5 equiv.) dissolved in 80 mL of THF was added dropwise over 20 min via addition funnel, and the resulting reaction mixture was allowed to warm to room temperature and stirred overnight.
[0604] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5).
[0605] The reaction mass was quenched with saturated NH4Cl solution (500 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3×100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0606] The crude compound was subjected to column chromatography on silica gel (60-120 mesh) using 20% EtOAc / Hexane. Yield 169.0 g; Yield 60%.
[0607] ATX-0081: Process 2 [ka]
[0608] To a solution of 100 g of 4-aminobutanoic acid (1 eq.) in THF in an ice bath was added 1 N aqueous NaOH solution (1.065 L) (1.1 eq.) followed by 1.3 eq. of Boc anhydride sequentially using an addition funnel over a period of 15 min. The resulting solution was allowed to warm to room temperature and stirred for 4 h.
[0609] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5).
[0610] The reaction mass was quenched with 5% HCl (1 L) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3×200 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid.
[0611] The crude compound was subjected to column chromatography on silica gel (60-120 mesh) using 80-100% EtOAc / Hexanes. Yield: 161.0 g; Yield: 82%.
[0612] ATX-0081: Process 3 [ka]
[0613] To a solution of 3×17.8 g of 4-((tert-butoxycarbonyl)amino)butanoic acid (1 eq.) in DCM (350 mL) cooled in an ice bath, 2×25.1 g of EDC.HCl (1.5 eq.), Et3N (2.0 eq.) and 3×1.0 g of DMAP (0.1 eq.) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 3×20.0 g of alcohol (1.0 eq.) in DCM (150 mL) was added dropwise through an addition funnel at the same temperature and the resulting reaction mass was allowed to warm to room temperature and stirred under nitrogen atmosphere for 24 h.
[0614] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5).
[0615] The reaction mass was quenched with water (450 mL) and the organic layer was separated. The aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was stirred with saturated NaHCO3 solution (300 mL) for 5 min and the aqueous phase was extracted with EtOAc (3×150 mL). The organic layer was separated, dried over anhydrous Na2SO4, concentrated under reduced pressure and carried forward crude to next step. Yield 69.0 g (crude; required compound and alcohol);
[0616] ATX-0081: Process 4 [ka]
[0617] 69.0 g of pentadecan-8-yl 4-(tert-butoxycarbonyl) To a solution of 1 eq. (carbonylamino)butanoate was added TFA (10 eq.) in an ice bath and the resulting reaction solution was allowed to warm to room temperature and stirred under a nitrogen atmosphere for 3 hours.
[0618] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3). The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (450 mL) and then extracted with EtOAc (3 x 150 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0619] The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield 47.0 g; 57% for two steps.
[0620] ATX-0081: Process 5 [ka]
[0621] To a solution of 50.0 g of 4-bromobutyric acid (1.0 equiv.) in DCM (450 mL) in a 2 L RB flask cooled below 0° C., 86.0 g of EDC.HCl (1.5 equiv.), 83.3 mL of Et3N (2.0 equiv.), and 3.6 g of DMAP (0.1 equiv.) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 42.5 g of alcohol (1.0 equiv.) (by dissolving in 200 mL of DCM) was added using an addition funnel, and the resulting solution was allowed to warm to room temperature and stirred under nitrogen atmosphere for 24 h.
[0622] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7).
[0623] The reaction mass was quenched with water (250 mL) and the organic layer was separated. The aqueous layer was washed with DCM (2×150 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (150 mL) and then extracted with EtOAc (2×150 mL). The organic layer was separated and concentrated under reduced pressure.
[0624] The crude compound was subjected to column chromatography on silica gel (60-120 mesh silica gel) using 5% EtOAc / Hexane. Yield: 55.0 g; Yield: 63%
[0625] ATX-0081: Process 6 [ka]
[0626] To a solution of 2×20.0 g of pentadecan-8-yl 4-aminobutanoate (1 eq.), 2×18.5 g of (Z)-non-2-en-1-yl 4-bromobutanoate (1 eq.) in 180 mL of ACN, 2×17.6 g of potassium carbonate (2 eq.) was added and the resulting mixture was refluxed at 70° C. for 5 h under nitrogen atmosphere.
[0627] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.4). The reaction mass was filtered, washed with ACN (2 x 20 mL) and the filtrate was concentrated under reduced pressure.
[0628] The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 30% EtOAc / Hexane. SM (amine) was recovered. Yield 24.0 g; 36%.
[0629] ATX-0081: Process 7 [ka]
[0630] To a solution of 24.0 g of (Z)-non-2-en-1-yl 4-((4-oxo-4-(pentadecan-8-yloxy)butyl)amino)butanoate (1 eq.) in 250 mL of dry DCM was added 13.5 g of triphosgene (1 eq.), the reaction mixture was cooled to 0° C., and 18.4 mL of pyridine (5 eq.) was added dropwise over 10 min. The reaction mixture was stirred at 20° C. for 4 h.
[0631] The DCM was removed under reduced pressure and the mixture was taken up in pyridine (300 mL). After cooling to 0° C., 32.3 g of dimethylaminoethanethiol hydrochloride (5 eq.) was added in portions and the resulting solution was stirred overnight at 20° C. under a nitrogen atmosphere.
[0632] After TLC confirmation, the reaction mass was concentrated to dryness under reduced pressure. To this residue, 250 mL of EA and 200 mL (10%) of citric acid were added. The organic phase was separated and then the organic layer was washed again once with 10% citric acid (100 mL) and again once with 10% brine (200 mL). The obtained organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the crude product.
[0633] The first purification was performed on silica gel (100-200 mesh; 500 g). In a gradient elution, the compound was eluted with 70% EtOAc / Hexane. After concentration, the compound (22.0 g) appeared reddish in color. The second purification was performed using neutral alumina (400 g) with HPLC grade solvent. The compound was eluted with 15% EtOAc / Hexane and the pure fractions were concentrated under reduced pressure to give 19.0 g of a yellow liquid.
[0634] The product (14.0 g) was diluted with 200 mL of EtOH (HPLC grade), then 7.0 g of charcoal (50% W / W) was added to the solution and kept stirring at room temperature overnight. The resulting solution was filtered through a Celite pad and the filtrate was concentrated. Finally, it was dissolved in 120 mL of 50% EtOAc / Hexane and filtered through a cotton plug (to remove alumina and silica particles). The mixture was concentrated under reduced pressure and the final compound (11.5 g) appeared pale yellow in color.
[0635] The second batch (5.0 g) was diluted with 80 mL of EtOH (HPLC grade), then 2.5 g of charcoal (50% W / W) was added to the solution and kept stirring at room temperature overnight. The resulting solution was filtered through a Celite pad and the filtrate was concentrated. Finally, it was dissolved in 60 mL of 50% EtOAc / Hexane, filtered through a cotton plug (to remove alumina and silica particles) and concentrated under reduced pressure. The final compound (4.0 g) appeared reddish yellow. Yield 15.5 g; 51%.
[0636] ATX-0081: 1 H-NMR(PPM,400MHz,CDCl3):δ=5.62(m,1),5.51(m,1),4.86(m,1),4.62(d,J=6.0Hz,2),3.37(brs,4),3.01(t,J=7.1Hz, 2),2.51(t,J=7.1Hz,2),2.31(m,4),2.26(s,6),2.07(m,2),1.89(brs,4),1.42~1.57(4),1.16~1.40(28),0.82~0.91(9) Example 15: Synthesis of ATX-0085
[0637] FIG. 15 shows a synthetic route to ATX-0085, which is further described below.
[0638] ATX-0085: Process 1 [ka]
[0639] In a 500 mL single-neck RB flask, 30.0 g of heptanoic acid (1 eq.) dissolved in 200 mL of DCM was placed and then 26.7 mL of oxalyl chloride (1.5 eq.) was added slowly at 0° C. with stirring under nitrogen atmosphere, followed by 1 mL of DMF (catalyst). The resulting reaction mixture was stirred at room temperature for 2 hours.
[0640] In a separate 1-liter two-neck RB flask, 40.5 g of N,O-dimethylhydroxylamine hydrochloride (2 eq.) in DCM (250 mL) was added with an addition funnel of 86.6 mL of trimethylamine (3 eq.) stirred at 0° C. After concentrating under reduced pressure, the above acid chloride was added dropwise over 20 min with an addition funnel by dissolving it in DCM (100 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature under nitrogen atmosphere for 3 h.
[0641] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL).
[0642] The organic layer was separated and the aqueous layer was washed with DCM (3×100 mL). The combined organic layers were concentrated under reduced pressure.
[0643] The crude compound was subjected to column chromatography (60-120 silica gel) using 10% EtOAc / Hexanes. Yield: 38.0 g; 84%.
[0644] ATX-0085: Process 2 [ka]
[0645] To a solution of 62.3 g of hexylmagnesium bromide (1.5 eq.) in ether in a 1 L two-neck round-bottom RB flask stirred at 0° C. under nitrogen atmosphere was added 38.0 g of N-methoxy-N-methylheptanamide (1 eq.) dissolved in 250 mL of ether and the resulting reaction mixture was stirred at room temperature for 4 h.
[0646] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7).
[0647] The reaction mass was quenched with saturated NH4Cl solution (200 mL). The organic layer was separated and the aqueous layer was washed with ether (2×100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0648] The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 2% EtOAc / Hexanes. Yield: 30.8 g; Yield: 71%.
[0649] ATX-0085: Process 3 [ka]
[0650] To a solution of 30.0 g of tridecan-7-one (1 eq.) in 200 MeOH / THF (10:1, v:v) was added 8.5 g of sodium borohydride (1.5 eq.) at 0° C. and the resulting solution was stirred at room temperature for 2 h.
[0651] The progress of the reaction was monitored by TLC (10% EtOAc / Hexanes; Rf: 0.5).
[0652] The reaction mass was quenched with saturated NH4Cl solution (80 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (200 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 70 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 27.2 g; 90%.
[0653] ATX-0085: Process 4 [ka]
[0654] To a solution of 50.0 g of 4-aminobutanoic acid (1 eq.) dissolved in THF / aqueous NaOH solution (490 mL) was added sequentially over 15 min using an addition funnel followed by 140 mL of Boc anhydride (1.3 eq.) at 0° C. The resulting solution was stirred at room temperature for 4 h.
[0655] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.5 ).
[0656] The reaction mass was quenched with 5% HCl (250 mL) followed by addition of EtOAc (300 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (3×150 mL). The combined organic layers were concentrated under reduced pressure to give a gummy liquid. Yield 80.0 g; Yield 81%. Confirmed by 1H NMR. Note: Boc-acid (Int4) with some impurity (20-30%) was confirmed by 1H NMR and was reflected in the yields of step 5 and step 6.
[0657] ATX-0085: Process 5 [ka]
[0658] To a solution of 10.0 g of 4-((tert-butoxycarbonyl)amino)butanoic acid (1 eq.) dissolved in DCM (200 mL) and cooled below 0° C., 12.2 g of EDC.HCl (1.3 eq.), 20.4 mL of Et3N (3 eq.), and 601 mg of DMAP (0.1 eq.) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, alcohol was added at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature under nitrogen atmosphere for 24 h.
[0659] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.5).
[0660] The reaction mass was quenched with water (150 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2 x 75 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then EtOAc (200 mL) was added. The organic layer was separated and concentrated under reduced pressure and taken forward crude to next step. Yield 8.0 g (crude; required compound and alcohol).
[0661] ATX-0085: Process 6 [ka]
[0662] To a solution of 8.0 g of tridecan-7-yl 4-((tert-butoxycarbonyl)amino)butanoate (1 eq.) in 65 mL of DCM was added 15.7 mL of TFA (10 eq.) at 0° C. and stirred at room temperature for 3 h under nitrogen atmosphere.
[0663] The progress of the reaction was monitored by TLC (10% MeOH in CHCl3; Rf: 0.3).
[0664] The reaction mass was concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then extracted with EtOAc (3 x 100 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography using (60-120 mesh silica gel; 4% MeOH / CHCl3 and 1 mL triethylamine) to recover the alcohol. Yield 3.5 g; 25% for two steps; confirmed by mass.
[0665] ATX-0085: Process 7 [ka]
[0666] To 20.0 g of hexanoic acid (1 equiv.) dissolved in 150 mL of DCM was slowly added 22.1 mL of oxalyl chloride (1.5 equiv.) at 0° C. with stirring under nitrogen atmosphere, followed by 1 mL of DMF (catalyst). The resulting reaction mixture was stirred at room temperature for 2 h.
[0667] In a separate flask, 33.5 g of N,O-dimethylhydroxylamine hydrochloride (2 eq.) in DCM (250 mL) was added with an addition funnel of 71.7 mL of trimethylamine (3 eq.) stirred at 0° C. After concentrating under reduced pressure, the above acid chloride was added dropwise over 20 min with an addition funnel by dissolving it in DCM (100 mL) under nitrogen atmosphere. The resulting reaction solution was stirred at room temperature under nitrogen atmosphere for 3 h.
[0668] The progress of the reaction was monitored by TLC (20% EtOAc / Hexane; Rf: 0.5). The reaction mass was diluted with water (250 mL). The organic layer was separated and the aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure.
[0669] The crude compound was subjected to column chromatography (60-120 silica gel) using 10% EtOAc / Hexanes. Yield: 21.0 g; Yield: 76%.
[0670] ATX-0085: Process 8 [ka]
[0671] To a solution of 33.0 g of pentylmagnesium bromide (1.5 eq.) in ether at 0° C. under a nitrogen atmosphere, 20.0 g of N-methoxy-N-methylhexanamide (1 eq.) dissolved in 220 mL of ether was added, and the resulting reaction mixture was stirred at room temperature for 4 hours.
[0672] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.6).
[0673] The reaction mass was quenched with saturated NH4Cl solution (200 mL). The organic layer was separated and the aqueous layer was washed with ether (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 2% EtOAc / Hexane. Yield 15.4 g; 72%.
[0674] ATX-0085: Process 9 [ka]
[0675] To a solution of 15.0 g of undecan-6-one (1 eq.) in 100 mL of MeOH / 15 mL of THF was added 4.9 g of sodium borohydride (1.5 eq.) at 0° C. and the resulting solution was stirred at room temperature for 2 h.
[0676] The progress of the reaction was monitored by TLC (10% EtOAc / Hexanes; Rf: 0.5).
[0677] The reaction mass was quenched with saturated NH4Cl solution (80 mL). The solvent was removed under reduced pressure and the crude obtained was partitioned between EtOAc (200 mL) and water (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 70 mL). The combined organic layers were concentrated under reduced pressure to give a white solid. Yield 13.9 g; white solid; 92%
[0678] ATX-0085: Process 10 [ka]
[0679] To a solution of 10.0 g of 5-bromopentanoic acid (1 equiv.) dissolved in DCM (300 mL) and cooled below 0° C., 13.7 g of EDC.HCl (1.3 equiv.), 23.0 mL of Et3N (3 equiv.), and 674 mg of DMAP were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 9.5 g of alcohol (1 equiv.) was added at the same temperature by dissolving in DCM (150 mL) using an addition funnel and stirred at room temperature for 24 h under nitrogen atmosphere.
[0680] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.7).
[0681] The reaction mass was quenched with water (200 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×100 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was washed with saturated NaHCO3 solution (100 mL) and then EtOAc (3×100 mL) was added. The organic layer was separated and concentrated under reduced pressure and carried forward crude. The crude compound was subjected to column chromatography (60-120 mesh silica gel) using 5% EtOAc / Hexane to recover SM (alcohol). Yield 11.6 g; 62%.
[0682] ATX-0085: Process 11 [ka]
[0683] To a solution of 4.5 g of tridecan-7-yl 4-aminobutanoate (1 eq.), 5.2 g of undecan-6-yl 5-bromopentanoate (1 eq.) in ACN, 3.0 g of potassium carbonate (1.4 eq.) was added and the resulting mixture was refluxed at 90° C. for 4 hours under a nitrogen atmosphere.
[0684] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.45).
[0685] The reaction mass was filtered, washed with ACN (2×20 mL) and the filtrate was concentrated under reduced pressure. The crude compound was subjected to column chromatography (100-200 mesh silica gel) using 20% EtOAc / Hexane. SM (amine and bromo compounds) were recovered. Yield, 2.2 grams of pure compound; 25% yield; and 1.1 grams of mixture. Confirmed by mass.
[0686] ATX-0085: Process 12 [ka]
[0687] To a solution of 2.2 g of undecan-6-yl 5-((4-oxo-4-(tridecan-7-yloxy)butyl)amino)pentanoate (1 eq.) dissolved in dry DCM, 1.6 mL of trimethylamine (3 eq.) and 604 mg of triphosgene (0.5 eq.) were added at 0° C. in 5 min intervals under nitrogen atmosphere. The resulting solution was stirred at room temperature under nitrogen atmosphere for 1 h. The resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere.
[0688] To a suspension of 684 mg of sodium hydride (7 eq.) in dry THF (30 mL) in a stirred flask at 0° C. under nitrogen atmosphere, 2.0 g of 2-(dimethylamino)ethane-1-thiol hydrochloride (3.5 eq.) was added and stirring was continued for 5 min under nitrogen atmosphere. To the resulting solution, the above carbonyl chloride dissolved in THF (50 mL) was slowly added via syringe over a period of about 10 min. The resulting solution was stirred overnight at room temperature under nitrogen atmosphere.
[0689] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5; PMA char).
[0690] The reaction mass was quenched with saturated NH4Cl (40 mL) followed by addition of EtOAc (100 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography. The first purification was carried out using silica gel (100-200 mesh). 5.0 g of crude compound was purified by column chromatography using 9.0 g of ethyl acetate (1.0 g). Adsorbed onto silica gel and poured onto 70 g of silica gel in a column. Compound was eluted with 50% EtOAc / Hexane. A second purification was performed using neutral alumina with HPLC grade solvent. 2.0 g of crude compound was adsorbed onto 7.0 g of neutral alumina and the resultant was poured onto 40 g of neutral alumina in a column. Compound was eluted with 25% EtOAc / Hexane. Amount 1.4 g; Yield 51%. 1 Confirmed by H NMR.
[0691] ATX-0085 1 H-NMR(PPM,400MHz,CDCl3):δ=4.87(m,2),3.36(brs,4),3.02(t,J=7.1Hz,2),2.52(t,J=7.1Hz,2) ,2.31(m,4),2.27(s,6),1.88(brs,2),1.56~1.66(4),1.46~1.54(8),1.21~1.34(30),0.89(m,12). Example 15: Synthesis of ATX-0134
[0692] FIG. 16 shows a synthetic route to ATX-0134, which is further described below.
[0693] ATX-0134: Process 1 [ka]
[0694] To a stirred solution of 50.0 g of methyl 2-bromoacetate (1 eq.) in 400 mL of DMF in a 1 L single-neck RB flask, 90.3 g of potassium carbonate (2 eq.) was added followed by 17.5 g of benzylamine (0.5 eq.) under a nitrogen atmosphere at ice bath temperature, and the resulting reaction mixture was allowed to warm to room temperature and continued to stir for 36 h.
[0695] The progress of the reaction was monitored by TLC (20% EtOAc / Hexanes; Rf: 0.4; ninhydrin charcoal).
[0696] The reaction mass was diluted with ice water (1 L) and then EtOAc (250 mL) was added. The organic layer was separated and the aqueous layer was washed with EtOAc (3×100 mL). The combined organic layers were washed again with ice water (500 mL) and the resulting organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure.
[0697] The crude compound was subjected to column chromatography on silica gel (60-120 mesh) using 15-20% EtOAc / Hexanes. Yield: 35.0 g; Yield: 85%.
[0698] ATX-0134: Process 2 [ka]
[0699] 10.5 g of 10% Pd / C was added to a 500 mL hydrogenation flask containing 35.0 g of dimethyl 2,2'-(benzylazanediyl)diacetate in EtOAc and the reaction mass was hydrogenated using a Parr shaker (60 psi) until the starting material disappeared (2 h).
[0700] The progress of the reaction was monitored by TLC (5% MeOH / CHCl3; Rf: 0.5; ninhydrin charcoal).
[0701] The reaction mass was filtered through a pad of Celite and washed with EtOAc (2×60 mL). The combined filtrate was concentrated under reduced pressure to give 30.0 g (crude).
[0702] ATX-0134: Process 3 [ka]
[0703] To a solution of 30.0 g of dimethyl 2,2'-azanediyl diacetate (1.0 equiv.) in THF, 38.7 mL of triethylamine (1.5 equiv.) was added followed by 55.5 mL of Boc anhydride (1.3 equiv.) using an addition funnel at ice bath temperature. The resulting reaction solution was stirred at room temperature overnight under a nitrogen atmosphere.
[0704] The progress of the reaction was monitored by TLC (40% EtOAc / Hexanes; Rf: 0.5).
[0705] The reaction mass was diluted with water (250 mL) and then EtOAc (150 mL) was added. The organic layer was separated and the aqueous layer was washed with EtOAc (2×100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude compound was subjected to column chromatography on silica gel (60-120 mesh) using 15%-20% EtOAc / Hexane. Yield 35.0 g; 96%.
[0706] ATX-0134: Process 4 [ka]
[0707] To a solution of 35.0 g of dimethyl 2,2'-((tert-butoxycarbonyl)azanediyl)diacetate (1.0 eq.) in THF stirred at ice bath temperature was added an aqueous solution of 16.8 g of lithium hydroxide (75 mL of 5.3 M) (3 eq.). The resulting reaction solution was stirred at room temperature under a nitrogen atmosphere for 5 hours.
[0708] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.2).
[0709] The reaction mass was quenched with 5% HCl (400 mL) and then EtOAc (200 mL) was added. The organic layer was separated and the aqueous layer was washed with EtOAc (2×100 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude compound was subjected to column chromatography on silica gel (60-120 mesh) using 100% EtOAc. Yield 29.0 g; 93%.
[0710] ATX-0134: Process 5 [ka]
[0711] 1 2,2'-((tert-butoxycarbonyl)azanediyl)diacetic acid 233.22 0.051 1.0
[0712] 2 Alcohol 228.42 0.102 2.0
[0713] 3 EDC.HCl 191.70 0.154 3.0
[0714] 4 Triethylamine 101 0.154 3.0
[0715] 5 DMAP 122.17 0.002 0.1
[0716] 6 DCM 400mL
[0717] To a solution of 12.0 g of 4,4-((tert-butoxycarbonyl)azanediyl)dibutanoic acid (1 eq.) in 250 mL of DCM cooled to 0° C.-50° C. (ice bath), 29.5 g of EDC.HCl (3 eq.), 21.4 mL of Et3N (3 eq.) and 628 mg of DMAP (0.1 eq.) were added sequentially at 10 min intervals under nitrogen atmosphere. To this resulting solution, 23.5 g of alcohol (2 eq.) in 150 mL of DCM was added through an addition funnel at the same temperature and the resulting reaction mass was allowed to warm to room temperature and stirred under nitrogen atmosphere for 24 h.
[0718] The progress of the reaction was monitored by TLC (10% EtOAc in hexanes; Rf: 0.6; PMA charred).
[0719] The reaction mass was quenched with water (100 mL) and then the organic layer was separated. The aqueous layer was washed with DCM (2×80 mL). The combined organic layers were concentrated under reduced pressure. The crude obtained was stirred with saturated NaHCO3 solution (100 mL) for 5 min to remove unreacted acid and then EtOAc (2×80 mL) was added. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude compound was subjected to column chromatography on silica gel (60-120 mesh) using 2-3% EtOAc / Hexane. Yield 15.0 g; 44%.
[0720] ATX-0134: Process 6 [ka]
[0721] To a solution of 15.0 g of di(pentadecan-8-yl) 2,2-((tert-butoxycarbonyl)azanediyl) diacetate (1 eq.) in 120 mL of DCM at 0 °C-50 °C (ice bath) was added 17.7 mL of TFA (10 eq.) and the reaction mass was allowed to warm to room temperature and stirred under nitrogen atmosphere for 4 h.
[0722] The progress of the reaction was monitored by TLC (10% EtOAc / Hexanes; Rf: 0.5).
[0723] The reaction mass was concentrated under reduced pressure and the crude obtained was stirred with saturated NaHCO3 solution (100 mL) for 5 min (to remove traces of TFA) and the aqueous phase was extracted with EtOAc (3 x 100 mL). The organic layer was separated and concentrated under reduced pressure. The crude compound was subjected to column chromatography on silica gel (60-120 mesh) and the compound was eluted with 10% EtOAc / Hexane. Yield 10.4 g; 82%.
[0724] ATX-0134: Process 7 [ka]
[0725] To a solution of 1.5 g of di(pentadecan-8-yl) 2,2'-azanediyl diacetate (1 eq.) in 20 mL of dry DCM, 1.1 mL of trimethylamine (3 eq.) and 401 mg of triphosgene (0.5 eq.) were added at 5 min intervals at ice bath temperature and under nitrogen atmosphere. The resulting solution was then warmed to room temperature and stirred for 1 h under nitrogen atmosphere. After completion of starting material (verified by TLC), the resulting reaction mass was concentrated under reduced pressure and kept under nitrogen atmosphere. 1.1 g of 3-(diethylamino)propane-1-thiol (3 eq.) dissolved in 10 mL of THF was added to a suspension of 129 mg of sodium hydride (2 eq.) in dry THF (10 mL) cooled to 0°C-50°C under nitrogen atmosphere and stirring was continued for 5 min. To this resulting solution, the above carbamoyl chloride dissolved in THF (30 mL) was added via an addition funnel over a period of about 5 minutes at the same temperature. The resulting solution was allowed to warm to room temperature and was left stirring overnight under nitrogen atmosphere.
[0726] The progress of the reaction was monitored by TLC (10% MeOH / CHCl3; Rf: 0.5; PMA char).
[0727] The reaction mass was quenched with saturated NH4Cl (30 mL) followed by addition of EtOAc (50 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (2 x 40 mL). The combined organic layers were concentrated and the crude obtained was subjected to column chromatography. The first purification was carried out using neutral alumina (100 g). In gradient elution, the compound was eluted with 20% EtOAc / Hexane. The second purification was carried out using silica gel (100-200 mesh; 80 g) with HPLC grade solvent. The compound was eluted with 50% EtOAc / Hexane. Amount 680 mg; Yield 34%.
[0728] ATX-0134 1 H-NMR(PPM,400MHz,CDCl3):δ=4.91(m,2),4.21(s,2),4.16(s,2),2.95(t,J=7.1Hz,2),2.54( m,6),1.79(m,2),1.46~1.52(8),1.17~1.36(40),1.03(t,J=7.8Hz,6),0.87(t,J=7.1Hz,12). Example 15: Synthesis of ATX-0044 and ATX-0091 to ATX-0133.
[0729] ATX-0044, ATX-0085, ATX-0111, ATX-0132, ATX-0100, ATX-0117, ATX-0114, ATX-0115, ATX-0101, ATX-0106, ATX-0116, ATX-0122, ATX-0123, ATX-0124, ATX-0126, ATX-0129, and ATX-0133 were synthesized using the methods of the previous examples. Example 16: pKa Values
[0730] pK of cationic lipids in LNP or micelle formulations awas measured by the procedure of Jayaraman, 2012, Angew. Chem. Int. Ed., 51:8529-33, incorporated herein by reference. Lipid micelles or LNPs are diluted to 1 mM total lipid in universal buffers ranging from pH 3 to 12 in the presence of 0.06 mg / mL 6-(p-toluidino)-2-naphthalenesulfonic acid sodium salt (TNS) reagent (Sigma Aldrich), a pH-sensitive fluorescent probe. Anionic TNS molecules fluoresce when associated with the positively charged membrane surface, but do not fluoresce when free in solution, allowing the measurement of pKa. The TNS signal is measured with a spectral plate reader. The TNS signal is plotted as a function of pH and analyzed using a nonlinear (Boltzmann) to determine the pKa. a Determine.
[0731] The reagents used in the assay include: ·Hepes free acid, CAS:7365-45-9 (VWR, 0511-1KG or equivalent) MES, HPLC grade: (Sigma 105228-100G or equivalent) Ammonium Acetate, HPLC Grade: (Sigma 90335-100mL or equivalent) Sodium chloride, HPLC grade (VWR EM-MX0475-1 or equivalent) TNS (Sigma-Aldrich T9792-250mg or equivalent) ·hydrochloric acid DMSO Calcium and magnesium free DPBS (GE, SH30028.O2 or equivalent) H2O, HPLC grade (OmniSolv, WX0004-1 or equivalent).
[0732] Prepare a stock solution of Universal Buffer Solution (UB) in a polystyrene sterile storage bottle to prepare 1 L using the table below. [Table 2] The reagent is sterile filtered through a 0.2 μm filter. Preparation of UB solution involves adding 5 mL of 1 M HCl to 350 mL of stock solution.
[0733] To prepare the pH ladder, use centrifuge tubes (50 mL) with 20 mL of UB buffer (pH approx. 3) and different amounts of 2N NaOH. Stock solution of TNS at 1 mg / mL in DMSO. Add 60 μL of TNS (1 mg / mL) to 940 μL of water to obtain a working solution concentration of 0.06 mg / mL. Analyze 5 test samples (1 mL of LNP samples in PBS at 1 mM total lipid) and one reference sample per plate. Prepare samples of different pH values in wells with the addition of 25 μL of TNS at 0.06 mg / mL. Add 15 μL of test sample per well. Incubate the microplate in the dark at room temperature for 15 minutes. The TNS template can be used to format the data from the plate reader. Perform a nonlinear (Boltzmann) regression analysis of the samples in Origin Pro 8 or equivalent software.
[0734] The results are shown in Table 1. In general, increasing lipophilicity via esters near the ionizable head group lowers the measured pKa while making the calculated pKa more basic. Adding lipophilicity to the alcohol while shortening the ester chain length can have a large effect on the measured pKa. For example, shortening the ester to a butanoate has no effect when the lipophilicity of the alcohol is increased to a branched alkyl group (see ATX-0057 and ATX-0058 vs. ATX-0002). Larger effects are seen when the esters are shortened to acetate, e.g., 1-branched / 1-Z-2-nonenol esters ATX-0061 / ATX-0064 (Δ=-0.90) and ATX-0063 (Δ=-0.7), and acetate / bis-branched esters ATX-0062 / ATX-0065 (Δ=-3.20) (Δ cLogP+4.0) versus ATX-0002.
[0735] Without being bound by theory, the results show the importance of increasing lipophilicity (as measured by cLogP) in combination with chain shortening in lowering the measured pKa compared to expectations and increasing the bioactivity of lipid nanoparticles. Example 17: In vivo EPO mRNA stability
[0736] Levels of mRNA in plasma were measured and compared after injection of nanoparticles containing different cationic lipids. Female Balb / c mice (6-8 weeks old) were used for the evaluation of plasma erythropoietin (EPO) levels in vivo after injection of lipid-encapsulated mouse EPO mRNA. All formulations were administered intravenously via tail vein injection at doses of 0.03 and 0.1 mg / kg in a dose volume of 5 mL / kg. Terminal blood collection was performed via cardiac puncture under 2% isoflurane 6 hours after formulation injection. Blood was collected in 0.109 M citrate buffer tubes and processed by centrifugation at 5000 rpm for 10 min. Serum was collected and EPO mRNA levels were analyzed. The results are shown in Figure 17. The results show substantial improvements for ATX-0057, ATX-0081, ATX-0082, ATX-0083, ATX-0084, ATX-0085, ATX-0086, and ATX-0087 over ATX-0002. Example 18: In vivo mouse Factor VII silencing and EPO expression
[0737] A liver-directed in vivo screen of liposomal libraries was used to test a series of compounds that promote high levels of siRNA-mediated gene silencing in hepatocytes (cells containing liver parenchyma). The blood clotting factor Factor VII is a preferred target gene for assaying functional siRNA delivery to the liver. Because this factor is produced specifically in hepatocytes, gene silencing indicates good delivery to the parenchyma as opposed to delivery to cells of the reticuloendothelial system (e.g., Kupffer cells). Furthermore, Factor VII is a secreted protein that can be easily measured in serum, without the need to euthanize the animals. Silencing at the mRNA level can be easily determined by measuring the levels of the protein. This is due to the short half-life of the protein (2-5 hours). Compositions with siRNA directed to Factor VIII were formulated with lipids, and comparison samples phosphate-buffered saline (PBS). Female C57BL / 6 mice (6-8 weeks old) were used for FVII siRNA knockdown (KD) experiments.
[0738] All formulations were administered intravenously via tail vein injection at a dose of 5 mg / kg, and at doses of 0.03 and 0.1 mg / kg. Terminal blood collection was performed via cardiac puncture under 2% isoflurane 48 hours after formulation injection. Blood was collected into 0.109 M citrate buffer tubes and processed by centrifugation at 1200G for 10 minutes. Plasma was collected and factor VII protein levels were analyzed by a chromogenic assay (Biophen FVII, Aniara Corporation). A standard curve was constructed using samples from PBS-injected mice, and relative factor VII expression was determined by comparing the treatment groups with untreated PBS controls. Results showed that ATX-0057 and ATX-0058 were substantially more effective than ATX-002 at both 0.03 and 0.1 mg / kg (Figure 18).
[0739] Table 1 shows the knockdown obtained from lipid nanoparticles comprising the lipids disclosed herein.
[0740] Epo expression was measured following delivery of mRNA using lipid nanoparticles containing the lipids described herein.
[0741] Female Balb / c mice (6-8 weeks old) were used for evaluation of EPO protein expression in vivo after delivery of lipid-encapsulated mouse EPO mRNA. All formulations were administered intravenously via tail vein injection at doses of 0.03 and 0.1 mg / kg at a dose volume of 5 mL / kg. Terminal blood collection was performed via cardiac puncture under 2% isoflurane 6 hours after formulation injection. Blood was collected in 0.109 M citrate buffer tubes and processed by centrifugation at 5000 rpm for 10 min. Serum was collected and EPO protein levels were analyzed by ELISA assay (R&D systems). A standard curve was constructed using samples from PBS-injected mice, and relative factor VII expression was determined by comparing the treated groups with untreated PBS controls. Results showed that EPO mRNA was expressed in substantially higher amounts in ATX-0057 nanoparticles than in ATX-002 at 0.1 mg / mL (Figure 19).
[0742] According to a preferred embodiment of the present invention, for example, the following is provided: (Section 1) A compound of formula I, [ka] During the ceremony, R1 is a branched acyclic alkyl or alkenyl of 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L1 is a linear alkane of 1 to 15 carbons; R2 is a linear alkyl or alkenyl of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons, or a branched acyclic alkyl or alkenyl of 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L2 is a linear alkane of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons; X is O or S; R3 is a linear alkane of 1, 2, 3, 4, 5, or 6 carbons; R4 and R5 are the same or different and are each a straight or branched chain acyclic alkyl of 1, 2, 3, 4, 5, or 6 carbons; Or a pharma- ceutically acceptable salt or solvate thereof. (Section 2) The compound is represented by the formula ATX-0082, ATX-0085, ATX-0083, ATX-0121, ATX-0091, ATX-0102, ATX-0098, ATX-0092 2. The compound according to claim 1, which is selected from the group consisting of ATX-0084, ATX-0095, ATX-0125, ATX-0094, ATX-0109, ATX-0110, ATX-0118, ATX-0108, ATX-0107, ATX-0093, ATX-0097, and ATX-0096. [ka] [ka] [ka] [ka] [ka] (Section 3) The compound according to claim 1, wherein R1 has 8, 9, 10, 11, 12, 13, 14, 16, or 17 carbons. (Section 4) The compound according to item 1, wherein R1 contains two identical alkyl or alkenyl groups. (Section 5) Item 1. The compound according to item 1, wherein R1 contains an alkenyl group. (Section 6) Item 1. The compound according to item 1, wherein R2 is alkenyl. (Section 7) Item 3. The compound according to item 1, wherein R2 is a branched non-cyclic alkyl. (Section 8) The compound according to claim 1, wherein L2 has 4, 5, 6, or 7 carbons. (Section 9) A compound of formula I, [ka] During the ceremony, R1 is a branched acyclic alkyl or alkenyl of 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L1 is a linear alkane of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons; R2 is a linear alkyl or alkenyl of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons, or a branched acyclic alkyl of 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L2 is a linear alkane of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons; X is O or S; R3 is a linear alkane of 1, 2, 3, 4, 5, or 6 carbons; R4 and R5 are the same or different and each represents 1, 2, 3, 4, 5, or is a 6 carbon straight or branched chain acyclic alkyl; a 1 mM solution of the compound has a pKa of 5.6 to 7.0 as measured by fluorescence of 6-(p-toluidino)-2-naphthalenesulfone; The compound has a c-LogD value of 10 to 14. Or a pharma- ceutically acceptable salt or solvate thereof. (Section 10) 10. The compound according to item 9, wherein the compound is selected from the group consisting of compounds of formulae ATX-0111, ATX-0132, ATX-0134, ATX-0100, ATX-0117, ATX-0114, ATX-0115, ATX-0101, ATX-0106, ATX-0116, ATX-0086, ATX-0058, ATX-0081, ATX-0123, ATX-0122, ATX-0057, ATX-0088, ATX-0087, ATX-0124, ATX-0126, ATX-0129, and ATX-0123. [ka] [ka] [ka] [ka] [ka] (Section 11) Item 10. The compound according to item 9, wherein R1 has 12, 13, 14, 16, or 17 carbons. (Section 12) Item 10. The compound according to item 9, wherein R1 contains two identical alkyl or alkenyl groups. (Section 13) 10. The compound according to item 9, wherein R1 contains an alkyl group. (Section 14) Item 10. The compound according to item 9, wherein R2 is alkenyl. (Section 15) Item 10. The compound according to item 9, wherein R2 is branched non-cyclic alkyl. (Section 16) 10. The compound according to claim 9, wherein L1 and L2 independently have 1, 2, or 3 carbons. (Section 17) The compound according to item 9, wherein L1 and L2 both have 3 carbons. (Section 18) Item 10. The compound according to item 9, wherein R3 is propylene or butylene. (Section 19) 10. The compound according to claim 9, wherein said c-LogD value is at least 11 and whose measured pKa is more basic than 6. (Section 20) A compound of formula I, [ka] During the ceremony, R1 is a branched acyclic alkyl of 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22 carbons; L1 is a linear alkane of 1, 2, or 3 carbons; R2 is a linear alkenyl of 8, 9, 10, 11, or 12 carbons or a branched acyclic alkyl of 12, 13, 14, 16, or 17 carbons; L2 is a linear alkane of 1, 2, or 3 carbons; X is O or S; R3 is a 2 or 3 carbon straight chain alkane; R4 and R5 are the same or different and each is a 1 or 2 carbon straight or branched chain acyclic alkyl; Or a pharma- ceutically acceptable salt or solvate thereof.
Claims
1. 1. A pharmaceutical composition comprising lipid nanoparticles encapsulating a nucleic acid, wherein the lipid nanoparticles is represented by formula I 【Chemistry 1】 or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, R 1 is a branched acyclic alkyl or branched acyclic alkenyl of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 carbons; L 1 is a straight chain alkylene of 1 to 7 carbons; R 2 is a straight chain alkenyl of 8 to 10 carbons; L 2 is a straight chain alkylene of 6 or 7 carbons; or R 2 is a branched acyclic alkyl of 10, 11, 12, 13, 14, 15, 16, 17, or 18 carbons; L 2 is a straight chain alkylene of 4, 5, 6, or 7 carbons; X is O or S; R 3 is a linear alkylene of 1, 2, 3, 4, 5, or 6 carbons; R 4 and R 5 are the same or different and are each a straight or branched chain acyclic alkyl of 1, 2, 3, 4, 5, or 6 carbons; Pharmaceutical compositions.
2. 2. The pharmaceutical composition of claim 1, wherein the cationic lipid is a compound of the formula ATX-0085, ATX-0098, ATX-0092, ATX-0110, ATX-0118, ATX-0108, ATX-0107, ATX-0093, ATX-0097, and ATX-0096. 【Chemistry 2-1】 【Chemistry 2-2】 【Chemistry 2-3】 A pharmaceutical composition selected from the group consisting of:
3. R 1 The pharmaceutical composition of claim 1 , wherein has 8, 9, 10, 11, 12, 13, 14, 16, or 17 carbons.
4. R 1 The pharmaceutical composition of claim 1 , wherein contains two identical alkyl or alkenyl groups.
5. R 1 The pharmaceutical composition of claim 1 , wherein comprises an alkenyl group.
6. R 2 The pharmaceutical composition of claim 1 , wherein is alkenyl.
7. R 2 The pharmaceutical composition of claim 1 , wherein is a branched non-cyclic alkyl.
8. A pharmaceutical composition comprising lipid nanoparticles encapsulating a nucleic acid, wherein said lipid nanoparticles are selected from the group consisting of ATX-0121, ATX-0091, ATX-0102, ATX-0095, ATX-0094, ATX-0109 and ATX-0125. 【Chemistry 8-1】 【Chemistry 8-2】 A pharmaceutical composition comprising a cationic lipid selected from:
9. A pharmaceutical composition comprising lipid nanoparticles encapsulating a nucleic acid, wherein said lipid nanoparticles are represented by the formula I 【Chemistry 9】 or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, R 1 is a branched acyclic alkyl of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 carbons; L 1 is a linear alkylene of 1, 2, or 3 carbons; R 2 is a straight chain alkenyl of 8 to 10 carbons; L 2 is methylene, X is O or S; R 3 is a linear alkylene of 2 or 3 carbons; R 4 and R 5 are the same or different and each is a 1 or 2 carbon straight or branched chain acyclic alkyl; Pharmaceutical compositions.
10. 1. A pharmaceutical composition comprising lipid nanoparticles encapsulating a nucleic acid, wherein said lipid nanoparticles are selected from the group consisting of ATX-0111, ATX-0100, ATX-0117, ATX-0114, ATX-0115, ATX-0101, ATX-0106, ATX-0116, ATX-0122, ATX-0123, ATX-0124, ATX-0126, and ATX-0129: 【Chemistry 10-1】 【Chemistry 10-2】 【Chemistry 10-3】 【Chemistry 10-4】 【Chemistry 10-5】 comprising a cationic lipid selected from Pharmaceutical compositions.
11. The cationic lipid is ATX-0095: 【Chemistry 11】 or a pharma- ceutically acceptable salt or solvate thereof.
12. The cationic lipid is ATX-0126 【Chemistry 12】 or a pharma- ceutically acceptable salt or solvate thereof.
Citation Information
Patent Citations
Cationic lipid
JP2013095755A
Lipids for therapeutic drug delivery formulations
JP2015523990A
Ionizable cationic lipids for RNA delivery
JP2016538343A
Releasable fusogenic lipids for nucleic acids delivery systems
WO2010057160A1
Ionizable cationic lipid for RNA delivery
WO2016081029A1
